[CAS NO. 357166-30-4] Pemetrexeddisodiumhemipentahydrate

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [357166-30-4]

Catalog

HY-13781

Brand

MCE

CAS

357166-30-4

DESCRIPTION [357166-30-4]

Overview

MDL	MFCD08458870
Molecular Weight	516.41
Molecular Formula	C20H24N5Na2O8.5
SMILES	O=C(O[Na])CC[C@@H](C(O[Na])=O)NC(C1=CC=C(CCC2=CNC(N=C(N)N3)=C2C3=O)C=C1)=O.[2.5H2O]

For research use only. We do not sell to patients.

15 Publications Citing Use of MCE

Summary

Pemetrexed disodium hemipenta hydrate is a novel antifolate , the K _i values of the pentaglutamate of LY231514 are 1.3, 7.2, and 65 nM for inhibits thymidylate synthase ( TS ), dihydrofolate reductase ( DHFR ), and glycinamide ribonucleotide formyltransferase ( GARFT ), respectively.

IC50 & Target

Ki: 1.3 nM (TS), 7.2 nM (DHFR), 65 nM (GARFT) ^[1]

In Vitro

Pemetrexed (LY231514) disodium is a novel classical antifolate, the antitumor activity of which may result from simultaneous and multipie inhibition of several key folate-requiring enzymes via its polyglutamated metabolites. Pemetrexed (LY231514) is one of the best substrates that is known for the enzyme FPGS (K _m =1.6 μM and V _max /K _m =621). It is likely that polyglutamation and the polyglutamated metabolites of LY231514 play profound roles in determining both the selectivity and the antitumor activity of this novel agent. Whereas LY23l5l4 only moderately inhibits TS (K _i =340 nM, recombinant mouse), the pentaglutamate of LY23l5l4 is 100-fold more potent (K _i =3.4 nM), making LY231514 one of the most potent folate-based TS inhibitors ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The group of mice treated with PC61 plus Pemetrexed demonstrates statistically longer survival than other groups. In a survival analysis, significantly better survival is observed in the group of mice treated with PC61 plus Pemetrexed compare with those treated with PC61 alone, rat IgG plus Pemetrexed, or no treatment ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02603003	Shanghai University of Traditional Chinese Medicine	Non-small Cell Lung Cancer(NSCLC)	June 2015	Phase 1
NCT03715933	Inhibrx, Inc.	Solid Tumors\|Malignant Pleural Mesothelioma\|Gastric Adenocarcinoma\|Colorectal Adenocarcinoma\|Sarcoma\|Pancreatic Adenocarcinoma\|Ewing Sarcoma\|Chondrosarcoma	October 10, 2018	Phase 1
NCT03050437	Samsung Medical Center	Carcinoma, Non-Small-Cell Lung	March 2013	Phase 2
NCT03158129	M.D. Anderson Cancer Center	Stage I Lung Non-Small Cell Cancer AJCC v7\|Stage IA Lung Non-Small Cell Carcinoma AJCC v7\|Stage IB Lung Non-Small Cell Carcinoma AJCC v7\|Stage II Lung Non-Small Cell Cancer AJCC v7\|Stage IIA Lung Non-Small Cell Carcinoma AJCC v7\|Stage IIB Lung Non-Small Cell Carcinoma AJCC v7\|Stage IIIA Lung Non-Small Cell Cancer AJCC v7	June 9, 2017	Phase 2
NCT01878617	St. Jude Children´s Research Hospital\|Genentech, Inc.\|National Cancer Institute (NCI)	Medulloblastoma	June 23, 2013	Phase 2
NCT04500704	Cancer Institute and Hospital, Chinese Academy of Medical Sciences\|Jiangsu Hansoh Pharmaceutical Co., Ltd.	Non Small Cell Lung Cancer	October 2020	Phase 3
NCT03348904	Incyte Corporation\|Bristol-Myers Squibb	Lung Cancer	December 27, 2017	Phase 3
NCT05299125	Latin American Cooperative Oncology Group\|Janssen, LP	Metastatic Non-small Cell Lung Cancers	November 2022	Phase 2
NCT00863512	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Lung Cancer	March 2009	Phase 3
NCT04253964	Wake Forest University Health Sciences\|National Cancer Institute (NCI)	Nonsmall Cell Lung Cancer\|Performance Status	July 1, 2020	Phase 2
NCT00424242	Northwestern University\|National Cancer Institute (NCI)	Brain and Central Nervous System Tumors\|Chronic Myeloproliferative Disorders\|Leukemia\|Lymphoma\|Lymphoproliferative Disorder\|Metastatic Cancer\|Multiple Myeloma and Plasma Cell Neoplasm\|Myelodysplastic Syndromes\|Precancerous Condition\|Secondary Myelofibrosis\|Unspecified Adult Solid Tumor, Protocol Specific	January 2007	Early Phase 1
NCT00771953	University of Maryland, Baltimore\|Tragara Pharmaceuticals, Inc.	Lung Cancer\|Non Small Cell Lung Cancer	November 2008	Phase 2
NCT04380636	Merck Sharp & Dohme LLC	Lung Neoplasms\|Carcinoma, Non-Small-Cell Lung	July 6, 2020	Phase 3
NCT02817633	Tesaro, Inc.	Neoplasms	July 8, 2016	Phase 1
NCT02951637	Shanghai Chest Hospital\|Ruijin Hospital\|Changhai Hospital	Lung Adenocarcinoma	December 2016	Phase 2
NCT03664024	Merck Sharp & Dohme LLC	Non-Small Cell Lung Cancer	October 30, 2018	Phase 2
NCT02001168	Xinjiang Medical University	Non-small Cell Lung Cancer	October 2013	Phase 3
NCT00684099	Hellenic Oncology Research Group\|University Hospital of Crete	Non Small Cell Lung Cancer	May 2006	Phase 1\|Phase 2
NCT01803282	Gilead Sciences	Pancreatic Cancer\|Non-small Cell Lung Cancer\|Esophagogastric Cancer\|Colorectal Cancer\|Breast Cancer	March 29, 2013	Phase 1
NCT01287520	Eli Lilly and Company	Advanced Cancer	November 2007	Phase 1
NCT05346952	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Advanced Non-squamous Non-small Cell Lung Cancer	January 25, 2022	Phase 3
NCT04245085	ETOP IBCSG Partners Foundation\|Roche Pharma AG	EGFRmutant Stage IIIB+C or IV Non-squamous NSCLC	September 29, 2020	Phase 2
NCT05555732	Daiichi Sankyo, Inc.\|AstraZeneca\|Merck Sharp & Dohme LLC	Metastatic Non Small Cell Lung Cancer	November 2022	Phase 3
NCT01303926	Gruppo Oncologico Italia Meridionale	Non-squamous Nonsmall Cell Neoplasm of Lung	January 2010	Phase 3
NCT00424723	Dana-Farber Cancer Institute\|Beth Israel Deaconess Medical Center\|Brigham and Women´s Hospital\|Massachusetts General Hospital	Neuroendocrine Tumors	December 2005	Phase 2
NCT00107419	Southwest Oncology Group\|National Cancer Institute (NCI)	Sarcoma	September 2005	Phase 2
NCT04736173	Arcus Biosciences, Inc.\|Gilead Sciences	Non Small Cell Lung Cancer\|Nonsquamous Non Small Cell Lung Cancer\|Squamous Non-small-cell Lung Cancer\|Lung Cancer	February 8, 2021	Phase 3
NCT01578668	Guangzhou Medical University	Lung Adenocarcinoma\|Brain Metastases	January 2012	Phase 2
NCT03770299	Bristol-Myers Squibb	Non-Small Cell Lung Cancer\|Non-Small-Cell Lung Carcinoma\|Circulating Tumor DNA	January 15, 2021	Phase 2
NCT03242616	Seoul National University Hospital	Breast Neoplasms	February 17, 2017	Phase 2
NCT04697628	Seagen Inc.\|Genmab	Cervical Cancer	February 22, 2021	Phase 3
NCT04524689	Sanofi	Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)	October 26, 2020	Phase 2
NCT04092283	National Cancer Institute (NCI)	Recurrent Lung Non-Small Cell Carcinoma\|Stage III Lung Cancer AJCC v8\|Stage IIIA Lung Cancer AJCC v8\|Stage IIIB Lung Cancer AJCC v8\|Stage IIIC Lung Cancer AJCC v8\|Unresectable Lung Non-Small Cell Carcinoma	April 9, 2020	Phase 3
NCT05200481	Intergroupe Francophone de Cancerologie Thoracique	Non Small Cell Lung Cancer\|ALK Gene Mutation	May 18, 2022	Phase 2
NCT00190840	Eli Lilly and Company	Carcinoma, Non-Small Cell Lung	September 2003	Phase 2
NCT02347917	Sumitomo Pharma Co., Ltd.	Malignant Pleural Mesothelioma\|Non-Small Cell Lung Cancer	February 2015	Phase 1\|Phase 2
NCT03366064	Asan Medical Center\|Korea Research Institute of Bioscience & Biotechnology	Non-small Cell Lung Cancer	November 9, 2017	Phase 1
NCT01473563	Eli Lilly and Company	Nonsquamous Non-Small Cell Neoplasm of Lung\|Non-Small Cell Lung Cancer Metastatic\|Non-Small Cell Lung Cancer Stage IIIB	December 2011	Phase 2
NCT01958372	Barbara Ann Karmanos Cancer Institute\|National Cancer Institute (NCI)	Adenocarcinoma of the Lung\|Adenosquamous Cell Lung Cancer\|Bronchoalveolar Cell Lung Cancer\|Large Cell Lung Cancer\|Recurrent Non-small Cell Lung Cancer\|Squamous Cell Lung Cancer\|Stage IIIA Non-small Cell Lung Cancer\|Stage IIIB Non-small Cell Lung Cancer	August 2014	Phase 1
NCT01187615	Bayer	Small Cell Lung Carcinoma	August 2010	Phase 1
NCT04129502	Takeda	Advanced+Metastatic Non-Small Cell Lung Cancer (NSCLC)	January 10, 2020	Phase 3
NCT01860508	Fudan University	Non-small Cell Lung Cancer	February 2013	Not Applicable
NCT03955042	Saint John´s Cancer Institute\|Eli Lilly and Company\|Chordoma Foundation	Chordoma	September 6, 2019	Phase 1
NCT00391274	Eli Lilly and Company	Non-Small Cell Lung Cancer	October 2006	Phase 3
NCT00786331	Gruppo Oncologico Italiano di Ricerca Clinica	Advanced Non-Small Cell Lung Cancer	July 2007	Phase 2
NCT04592666	Fudan University	Lung Cancer, Non-small Cell\|EGFR T790M\|EGFR Gene Mutation	October 9, 2020	Phase 2
NCT00308750	Eli Lilly and Company	Non-Small Cell Lung Cancer	March 2006	Phase 2
NCT04765059	AstraZeneca\|Parexel	Non-small Cell Lung Cancer	September 12, 2021	Phase 3
NCT00408226	CASI Pharmaceuticals, Inc.	Advanced Cancer\|Non-Small Cell Lung Cancer	October 2006	Phase 1\|Phase 2
NCT03830411	Xin-Hua Xu\|China Three Gorges University, Yichang, China	Nonsquamous Non-Small Cell Lung Cancer	March 13, 2019	Phase 2
NCT00389688	European Organisation for Research and Treatment of Cancer - EORTC	Lung Cancer	August 2006	Phase 2
NCT02419495	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Advanced Malignant Solid Neoplasm\|Clinical Stage III Cutaneous Melanoma AJCC v8\|Clinical Stage IV Cutaneous Melanoma AJCC v8\|Fallopian Tube Carcinoma\|Metastatic Lung Non-Small Cell Carcinoma\|Metastatic Malignant Solid Neoplasm\|Metastatic Melanoma\|Metastatic Renal Cell Carcinoma\|Ovarian Carcinoma\|Pathologic Stage III Cutaneous Melanoma AJCC v8\|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8\|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8\|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8\|Pathologic Stage IIID Cutaneous Melanoma AJCC v8\|Pathologic Stage IV Cutaneous Melanoma AJCC v8\|Primary Peritoneal Carcinoma\|Stage III Lung Cancer AJCC v8\|Stage III Renal Cell Cancer AJCC v8\|Stage IIIA Lung Cancer AJCC v8\|Stage IIIB Lung Cancer AJCC v8\|Stage IIIC Lung Cancer AJCC v8\|Stage IV Lung Cancer AJCC v8\|Stage IV Renal Cell Cancer AJCC v8\|Stage IVA Lung Cancer AJCC v8\|Stage IVB Lung Cancer AJCC v8\|Triple-Negative Breast Carcinoma\|Unresectable Lung Non-Small Cell Carcinoma\|Unresectable Melanoma\|Unresectable Renal Cell Carcinoma	June 26, 2015	Phase 1
NCT00370292	Eli Lilly and Company	Non Small Cell Lung Cancer	September 2006	Phase 2
NCT00732992	Pfizer	Neoplasm, Malignant	August 2008	Phase 1
NCT00363415	Eli Lilly and Company	Small Cell Lung Cancer	August 2006	Phase 3
NCT02919462	Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori\|Pierre Fabre Laboratories	Carcinoma, Non-Small-Cell Lung\|Secondary\|Advanced Stage IIIB\|High Thymidylate Synthase Expression	March 2016	Phase 2
NCT03918278	Merck Sharp & Dohme LLC	Neoplasms	June 19, 2019	Phase 1
NCT04153565	Merck Sharp & Dohme LLC	Mesothelioma	December 9, 2019	Phase 1
NCT04837716	M.D. Anderson Cancer Center	Metastatic Lung Non-Small Cell Carcinoma\|Recurrent Lung Non-Small Cell Carcinoma\|Stage IIIC Lung Cancer AJCC v8\|Stage IV Lung Cancer AJCC v8\|Stage IVA Lung Cancer AJCC v8\|Stage IVB Lung Cancer AJCC v8	March 18, 2021	Phase 1
NCT00380718	Eli Lilly and Company	Non-small Cell Lung Cancer	November 2006	Phase 4
NCT03507244	The First Hospital of Jilin University	Leptomeningeal Metastasis	April 12, 2018	Phase 1\|Phase 2
NCT04966663	University Health Network, Toronto\|Bristol-Myers Squibb	Non Small Cell Lung Cancer\|Complete Surgical Resection\|Circulating Tumor DNA	March 28, 2022	Phase 2
NCT04107103	AHS Cancer Control Alberta\|Alberta Cancer Foundation	SCCHN	March 19, 2020	Phase 2
NCT00691301	Gynecologic Oncology Group\|National Cancer Institute (NCI)\|GOG Foundation	Cervical Cancer	September 2008	Phase 2
NCT01502202	National Cancer Center, Korea\|AstraZeneca	Non Small Cell Lung Cancer\|Adenocarcinoma	March 2012	Phase 2
NCT00540241	Eli Lilly and Company	Non Small Cell Lung Cancer	September 2007
NCT03607539	Innovent Biologics (Suzhou) Co. Ltd.	Lung Neoplasms	August 23, 2018	Phase 3
NCT00190983	Eli Lilly and Company\|Gynecologic Oncology Group	Cervical Intraepithelial Neoplasia\|Uterine Neoplasms\|Genital Neoplasms, Female	February 2005	Phase 2
NCT00454194	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Lung Cancer	September 2007	Phase 2
NCT02185690	University Health Network, Toronto\|Novartis Pharmaceuticals	Lungcancer	January 11, 2018	Phase 1
NCT03709147	Marina Garassino\|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	Advanced LKB1-inactive Lung Adenocarcinoma	October 30, 2018	Phase 2
NCT00248495	Roswell Park Cancer Institute	Lung Cancer	June 8, 2005	Phase 2
NCT02886195	Fujian Cancer Hospital	EGFR Gene Mutation	July 2016	Phase 3
NCT01490437	Asan Medical Center	Urothelial Carcinoma	July 2008	Phase 2
NCT00703638	Masonic Cancer Center, University of Minnesota	Breast Cancer\|Colorectal Cancer\|Head and Neck Cancer\|Lung Cancer\|Mesothelioma\|Pancreatic Cancer\|Prostate Cancer\|Sarcoma	May 2008	Phase 1
NCT02725918	Guangdong Association of Clinical Trials	Non-small Cell Lung Cancer	April 1, 2016	Phase 2
NCT00794417	Regeneron Pharmaceuticals\|Sanofi	Advanced Carcinoma\|Non-small Cell Lung Cancer	November 30, 2008	Phase 1\|Phase 2
NCT00222729	University of Pittsburgh\|Eli Lilly and Company\|Genentech, Inc.	Cancer	November 2005	Phase 2
NCT03944772	AstraZeneca	Non-Small Cell Lung Cancer	June 25, 2019	Phase 2
NCT04716933	Merck Sharp & Dohme LLC\|Eisai Inc.	Nonsquamous Non-small Cell Lung Cancer	November 5, 2019	Phase 3
NCT00035061	Eli Lilly and Company	Urologic Neoplasms\|Metastases, Neoplasm		Phase 2
NCT04452214	Cantargia AB	Carcinoma, Non-Small-Cell Lung\|Urothelial Carcinoma\|Malignant Melanoma\|Head and Neck Squamous Cell Carcinoma	September 24, 2020	Phase 1
NCT02964013	Merck Sharp & Dohme LLC	Neoplasms	December 13, 2016	Phase 1
NCT00315861	SCRI Development Innovations, LLC\|GlaxoSmithKline\|Eli Lilly and Company	Ovarian Cancer\|Endometrial Cancer\|Cervical Cancer\|Lung Cancer	March 2006	Phase 1
NCT02264990	AbbVie	Non-squamous Non-small Cell Lung Cancer	September 30, 2014	Phase 3
NCT00034489	Eli Lilly and Company	Breast Neoplasms		Phase 2
NCT02654587	OSE Immunotherapeutics	Non Small Cell Lung Cancer	February 2016	Phase 3
NCT03317496	Pfizer	Non-small Cell Lung Cancer\|Urothelial Cancer	December 21, 2017	Phase 1\|Phase 2
NCT05017012	Merck Sharp & Dohme LLC	Advanced or Metastatic Solid Tumors	September 21, 2021	Phase 1
NCT00520936	Eli Lilly and Company\|Children´s Oncology Group	Osteosarcoma\|Medulloblastoma\|Sarcoma, Ewing´s\|Neuroblastoma (Measurable Disease)\|Neuroblastoma (Metaiodobenzylguanidine\|Positive Evaluable)\|Rhabdomyosarcoma\|Ependymoma\|Non-brainstem High-grade Glioma	September 2007	Phase 2
NCT03164694	Sun Yat-sen University	Lung Cancer	May 20, 2017	Phase 2
NCT00528281	GlaxoSmithKline	Lung Cancer, Non-Small Cell	September 20, 2007	Phase 1
NCT00365183	Pharmacyclics LLC.	Non-Small Cell Lung Carcinoma	June 2006	Phase 2
NCT03793179	National Cancer Institute (NCI)	Lung Non-Squamous Non-Small Cell Carcinoma\|Stage IIIB Lung Cancer AJCC v8\|Stage IIIC Lung Cancer AJCC v8\|Stage IV Lung Cancer AJCC v8\|Stage IVA Lung Cancer AJCC v8\|Stage IVB Lung Cancer AJCC v8	February 28, 2019	Phase 3
NCT00502567	AstraZeneca	Advanced Solid Tumor	January 2005	Phase 1
NCT02964689	Swiss Group for Clinical Cancer Research	Advanced Non-small Cell Lung Cancer\|KRAS Gene Mutation\|Lung Cancer	April 12, 2017	Phase 1
NCT01107626	ECOG-ACRIN Cancer Research Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group	Lung Cancer	August 12, 2010	Phase 3
NCT03228537	National Cancer Institute (NCI)	Biphasic Mesothelioma\|Epithelioid Mesothelioma\|Stage I Pleural Malignant Mesothelioma AJCC v7\|Stage IA Pleural Malignant Mesothelioma AJCC v7\|Stage IB Pleural Malignant Mesothelioma AJCC v7\|Stage II Pleural Malignant Mesothelioma AJCC v7\|Stage III Pleural Malignant Mesothelioma AJCC v7	November 3, 2017	Phase 1
NCT04153734	Kobe Minimally Invasive Cancer Center\|Merck Sharp & Dohme LLC	Locally Advanced Non-small Cell Lung Cancer	December 1, 2019	Phase 2
NCT01708993	Canadian Cancer Trials Group\|Oncolytics Biotech	Non Small Cell Lung Cancer	October 15, 2012	Phase 2
NCT01336842	University of California, Davis\|Novartis Pharmaceuticals	Solid Tumors\|Non-Small Cell Lung Cancer (NSCLC)	April 2011	Phase 1
NCT05501665	Vanderbilt-Ingram Cancer Center\|National Cancer Institute (NCI)\|Varian Medical Systems	Lung Non-Small Cell Carcinoma\|Stage IV Lung Cancer AJCC v8	January 31, 2023	Phase 1\|Phase 2
NCT00614965	Hellenic Oncology Research Group\|University Hospital of Crete	Non Small Cell Lung Cancer	November 2006	Phase 2
NCT00686959	Eli Lilly and Company	Non Small Cell Lung Cancer	September 2008	Phase 3
NCT02322281	Clovis Oncology, Inc.	Non-small Cell Lung Cancer	February 2015	Phase 3
NCT03564691	Merck Sharp & Dohme LLC	Neoplasms	July 11, 2018	Phase 1
NCT02607592	Sun Yat-sen University	Carcinoma?Non-Small-Cell Lung	August 2015	Phase 3
NCT02489903	EpicentRx, Inc.	Small Cell Carcinoma\|Carcinoma, Non-Small-Cell Lung\|Neuroendocrine Tumors\|Ovarian Epithelial Cancer	June 2015	Phase 2
NCT00541073	Centre Oscar Lambret\|National Cancer Institute (NCI)	Malignant Mesothelioma	June 2007	Phase 2
NCT01088620	WiSP Wissenschaftlicher Service Pharma GmbH\|Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH	Carcinoma, Non-Small-Cell Lung	April 2010	Phase 2
NCT02591615	Alliance Foundation Trials, LLC.\|Merck Sharp & Dohme LLC	Non-Small Cell Lung Cancer	March 2016	Phase 2
NCT00191750	Eli Lilly and Company	Carcinoma, Small Cell	July 2004	Phase 2
NCT02039674	Merck Sharp & Dohme LLC	Non-small Cell Lung Carcinoma	February 21, 2014	Phase 1\|Phase 2
NCT02944396	AbbVie	Non-Small Cell Lung Cancer	December 23, 2016	Phase 1
NCT00491075	M.D. Anderson Cancer Center\|Eli Lilly and Company	Renal Cell Carcinoma	December 2005	Phase 2
NCT01548144	M.D. Anderson Cancer Center	Advanced Cancers	April 2012	Phase 1
NCT01450384	Virginia Commonwealth University\|National Cancer Institute (NCI)	Unspecified Adult Solid Tumor	October 2011	Phase 1
NCT00227019	Heather Wakelee\|Eli Lilly and Company\|Genentech, Inc.\|Stanford University	Non-small Cell Lung Cancer (NSCLC)\|Lung Cancer\|Neoplasm Metastasis	March 2006	Phase 2
NCT01296568	Eli Lilly and Company	Advanced Cancer	February 2011	Phase 1
NCT00520845	Vanderbilt-Ingram Cancer Center\|National Cancer Institute (NCI)	Lung Cancer	October 2007	Phase 2
NCT05153408	Blueprint Medicines Corporation	Lung Neoplasm\|Carcinoma, Non-Small-Cell Lung\|Respiratory Tract Neoplasms\|Neoplasms\|Neoplasms by Site\|Lung Diseases\|Respiratory Tract Diseases\|Carcinoma, Bronchogenic\|Bronchial Neoplasms\|Adenocarcinoma\|Carcinoma\|Neoplasms by Histologic Type\|Neoplasms, Nerve Tissue\|EGFR C797S\|EGFR C797A\|EGFR L858R\|EGFR Exon 19 Deletion\|EGFR Gene Mutation\|EGF-R Positive Non-Small Cell Lung Cancer\|EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance\|EGFR Activating Mutation\|Thoracic Neoplasms\|Antineoplastic Agents\|Protein Kinase Inhibitors\|EGFR C797G\|EGFR C797X\|Non Small Cell Lung Cancer	January 13, 2022	Phase 1\|Phase 2
NCT00301808	Barbara Ann Karmanos Cancer Institute\|National Cancer Institute (NCI)	Lung Cancer	November 2005	Phase 2
NCT00733031	AstraZeneca	Cancer,\|Solid Tumors\|Advanced Solid Malignancies	August 2008	Phase 1
NCT00101842	Eli Lilly and Company	Carcinoma, Transitional Cell	December 2004	Phase 1\|Phase 2
NCT02124148	Eli Lilly and Company	Neoplasm Metastasis\|Colorectal Neoplasms\|Breast Cancer	June 18, 2014	Phase 1
NCT03242915	University of Michigan Rogel Cancer Center	Non-small Cell Lung Cancer	October 3, 2017	Phase 2
NCT03706703	Affiliated Cancer Hospital & Institute of Guangzhou Medical University	Lung Cancer	October 1, 2018	Phase 2
NCT00461786	Eli Lilly and Company\|Gynecologic Oncology Group	Ovarian Cancer\|Peritoneal Cancer	September 2004	Phase 2
NCT00351039	H. Lee Moffitt Cancer Center and Research Institute\|Genentech, Inc.\|Eli Lilly and Company	Non-Small Cell Lung Cancer	July 2006	Phase 1\|Phase 2
NCT03164616	AstraZeneca	Non Small Cell Lung Cancer NSCLC	June 1, 2017	Phase 3
NCT02568033	The Cooper Health System	Non Small Cell Lung Cancer	October 2013	Early Phase 1
NCT00490373	Eli Lilly and Company	Pancreatic Cancer	October 2003	Phase 2
NCT00310050	Wake Forest University Health Sciences\|National Cancer Institute (NCI)	Pancreatic Cancer	October 2005	Phase 1
NCT00394147	Fox Chase Cancer Center\|Eli Lilly and Company	Head and Neck Cancer	October 2006	Phase 2
NCT03559049	University of Michigan Rogel Cancer Center\|Merck Sharp & Dohme LLC\|Clovis Oncology, Inc.	Stage IV Non-small Cell Lung Cancer	December 24, 2018	Phase 1\|Phase 2
NCT04816214	Novartis Pharmaceuticals\|Novartis	Carcinoma, Non-Small-Cell Lung	September 22, 2021	Phase 3
NCT05118854	M.D. Anderson Cancer Center\|Amgen	Lung Cancer	March 30, 2022	Phase 2
NCT03088540	Regeneron Pharmaceuticals\|Sanofi	Carcinoma?Non-Small-Cell Lung\|Lung Carcinomas, Non-Small-Cell\|Non-small-cell Lung Carcinoma\|Nonsmall Cell Lung Cancer	May 29, 2017	Phase 3
NCT00509366	Duke University\|Eli Lilly and Company	Non Small Cell Lung Cancer	May 2007	Phase 2
NCT02607423	ECOG-ACRIN Cancer Research Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group	Stage IIIA Non-Small Cell Lung Cancer	November 19, 2015	Phase 2
NCT00096187	Gynecologic Oncology Group\|National Cancer Institute (NCI)\|GOG Foundation	Gestational Trophoblastic Tumor	July 2005	Phase 2
NCT04022876	Aileron Therapeutics, Inc.	Non Small Cell Lung Cancer\|Small-cell Lung Cancer	September 3, 2019	Phase 1
NCT00377520	Eli Lilly and Company\|Gynecologic Oncology Group	Neoplasms\|Neoplasms by Site\|Urogenital Neoplasms\|Genital Neoplasms, Female\|Uterine Neoplasms\|Endometrial Neoplasms\|Cancer of Endometrium\|Endometrial Cancer\|Cancer of the Endometrium\|Endometrium Cancer\|Neoplasms, Endometrial	September 2006	Phase 2
NCT02134912	Southwest Oncology Group\|National Cancer Institute (NCI)	Adenocarcinoma of the Lung\|Large Cell Lung Cancer\|Recurrent Non-small Cell Lung Cancer\|Stage IV Non-small Cell Lung Cancer	August 2014	Phase 2
NCT03061058	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Stomach Neoplasms\|Chemotherapy Effect\|Chemotherapeutic Toxicity	April 1, 2013	Phase 3
NCT05012254	Fundación GECP	Non Small Cell Lung Cancer\|Brain Metastases, Adult\|Lung Cancer	November 18, 2021	Phase 2
NCT02383212	Regeneron Pharmaceuticals\|Sanofi	Advanced Cancer\|Advanced Malignancies	February 2, 2015	Phase 1
NCT04585490	Maximilian Diehn\|AstraZeneca\|Stanford University	Non Small Cell Lung Cancer\|NSCLC, Stage III\|Nsclc	August 25, 2021	Phase 3
NCT04943029	Wuhan Union Hospital, China	Non Small Cell Lung Cancer	August 20, 2021	Phase 2
NCT00383266	Washington University School of Medicine\|Eli Lilly and Company	Esophageal Neoplasms	October 2006	Phase 2
NCT03790228	Henan Cancer Hospital\|Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Non-squamous Cell Non-Small Cell Lung Cancer	March 22, 2019	Phase 1
NCT00976456	PD Dr. med. Wolfgang Schuette\|Roche Pharma AG\|Eli Lilly and Company\|Martha-Maria Krankenhaus Halle-Dölau gGmbH	Non-squamous Non-small Cell Lung Cancer	September 2009	Phase 3
NCT01531790	Jiangsu Simcere Pharmaceutical Co., Ltd.	Non-Small Cell Lung Cancer	September 2011	Phase 1
NCT01057589	Eli Lilly and Company	Head and Neck Neoplasms	February 2010	Phase 2
NCT01185847	Hoffmann-La Roche	Non-Squamous Non-Small Cell Lung Cancer	November 2010	Phase 2
NCT00604461	H. Lee Moffitt Cancer Center and Research Institute\|Genentech, Inc.	Mesothelioma	October 2007	Phase 1\|Phase 2
NCT02093962	Threshold Pharmaceuticals\|EMD Serono	Non-small Cell Lung Cancer	June 2014	Phase 2
NCT03515837	Merck Sharp & Dohme LLC	Non-small Cell Lung Cancer	June 29, 2018	Phase 3
NCT03647956	The University of Hong Kong	NSCLC Stage IIIB\|NSCLC Stage IV\|EGFR Activating Mutation	October 1, 2018	Phase 2
NCT00529100	Eli Lilly and Company	Non-Small Cell Lung Cancer	December 2005	Phase 1\|Phase 2
NCT00989690	Istituto Scientifico H. San Raffaele\|National Cancer Institute (NCI)	Lung Cancer	February 2008	Phase 3
NCT02142738	Merck Sharp & Dohme LLC	Non-Small Cell Lung Carcinoma	August 25, 2014	Phase 3
NCT03713944	Nasser Hanna\|Genentech, Inc.\|Big Ten Cancer Research Consortium	NSCLC Stage IV\|NSCLC, Recurrent	November 15, 2018	Phase 2
NCT01358968	Eli Lilly and Company	Cancer	June 2011	Phase 1
NCT03843853	The First Affiliated Hospital with Nanjing Medical University\|Jiangsu HanSoh Tharmaceutical Group Co., Ltd	Colorectal Neoplasms	May 1, 2019	Phase 2
NCT04538664	Janssen Research & Development, LLC	Carcinoma, Non-Small-Cell Lung	October 13, 2020	Phase 3
NCT03351842	Shanghai Pulmonary Hospital, Shanghai, China	Chemotherapy, Adjuvant\|Lung Adenocarcinoma, Stage I\|Treatment\|Histological Type of Neoplasm	September 1, 2017	Phase 2
NCT03023319	Nagla Abdel Karim\|Augusta University	Carcinoma, Non-Small-Cell Lung\|Mesothelioma\|Bladder Cancer\|Ovarian Cancer\|Peritoneal Cancer\|Thymoma\|Thymus Cancer\|Uterine Cervical Cancer	December 10, 2019	Phase 1
NCT00087100	Gynecologic Oncology Group\|National Cancer Institute (NCI)\|GOG Foundation	Endometrial Cancer	May 2006	Phase 2
NCT00906282	SCRI Development Innovations, LLC\|Eli Lilly and Company	Non Small Cell Lung Cancer	June 2009	Phase 2
NCT00191984	Eli Lilly and Company	Metastatic Colorectal Cancer	June 2004	Phase 2
NCT05504278	Innovent Biologics (Suzhou) Co. Ltd.	Advanced Non-Small Cell Lung Cancer	August 31, 2022	Phase 1
NCT04989283	National Cancer Institute (NCI)	Lung Non-Small Cell Carcinoma\|Stage IIB Lung Cancer AJCC v8\|Stage IIIA Lung Cancer AJCC v8\|Superior Sulcus Lung Carcinoma	September 9, 2021	Phase 2
NCT00190918	Eli Lilly and Company\|Gynecologic Oncology Group	Trophoblastic Neoplasms\|Uterine Neoplasms\|Hydatidiform Mole\|Choriocarcinoma	July 2006	Phase 2
NCT04993677	Seagen Inc.\|Merck Sharp & Dohme LLC	Melanoma\|Carcinoma, Non-Small- Cell Lung	October 6, 2021	Phase 2
NCT01397305	Isofol Medical AB	Rectal Cancer	April 14, 2011	Phase 1\|Phase 2
NCT03380871	BioNTech US Inc.\|Merck Sharp & Dohme LLC\|BioNTech SE	Carcinoma, Non-Small-Cell Lung\|Lung Cancer\|Nonsquamous Nonsmall Cell Neoplasm of Lung	May 4, 2018	Phase 1
NCT00216099	Christopher Sweeney, MBBS\|Eli Lilly and Company\|Walther Cancer Institute\|Hoosier Cancer Research Network	Prostate Cancer	February 2005	Phase 2
NCT00475657	Eli Lilly and Company	Small Cell Lung Cancer	October 2007	Phase 2
NCT02535325	National Cancer Institute (NCI)	Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma\|Stage III Lung Adenocarcinoma AJCC v7\|Stage III Lung Large Cell Carcinoma AJCC v7\|Stage III Lung Non-Small Cell Cancer AJCC v7\|Stage IIIA Lung Adenocarcinoma AJCC v7\|Stage IIIA Lung Large Cell Carcinoma AJCC v7\|Stage IIIA Lung Non-Small Cell Cancer AJCC v7\|Stage IIIB Lung Adenocarcinoma AJCC v7\|Stage IIIB Lung Large Cell Carcinoma AJCC v7\|Stage IIIB Lung Non-Small Cell Cancer AJCC v7\|Stage IV Lung Adenocarcinoma AJCC v7\|Stage IV Lung Large Cell Carcinoma AJCC v7\|Stage IV Lung Non-Small Cell Cancer AJCC v7	September 30, 2015	Phase 1
NCT04316351	Guangzhou Institute of Respiratory Disease\|Shanghai Junshi Bioscience Co., Ltd.	IIIb+IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy	April 1, 2020	Phase 2
NCT03544814	Shanghai Chest Hospital	Lung Adenocarcinoma\|EGFR Activating Mutation	January 1, 2015	Phase 2
NCT01001910	Albert Einstein College of Medicine\|National Cancer Institute (NCI)	Recurrent Fallopian Tube Carcinoma\|Recurrent Ovarian Carcinoma\|Recurrent Primary Peritoneal Carcinoma	July 2008	Phase 2
NCT03631199	Novartis Pharmaceuticals\|Novartis	Non-small Cell Lung Cancer	December 21, 2018	Phase 3
NCT00265785	Southwest Oncology Group\|National Cancer Institute (NCI)	Lung Cancer	July 2006	Phase 2
NCT00533429	Eli Lilly and Company\|Genentech, Inc.	Non-small Cell Lung Cancer	October 2007	Phase 2
NCT00950365	Albert Einstein College of Medicine\|National Cancer Institute (NCI)\|Eli Lilly and Company\|OSI Pharmaceuticals	Bronchioloalveolar Carcinoma\|Large Cell Lung Carcinoma\|Lung Adenocarcinoma\|Recurrent Non-Small Cell Lung Carcinoma\|Stage IIIB Non-Small Cell Lung Cancer\|Stage IV Non-Small Cell Lung Cancer	April 2006	Phase 2
NCT04061590	University of California, San Francisco\|Merck Sharp & Dohme LLC	Lung Non-Small Cell Carcinoma\|Stage I Lung Cancer AJCC v8\|Stage IA1 Lung Cancer AJCC v8\|Stage IA2 Lung Cancer AJCC v8\|Stage IA3 Lung Cancer AJCC v8\|Stage IB Lung Cancer AJCC v8\|Stage II Lung Cancer AJCC v8\|Stage IIA Lung Cancer AJCC v8\|Stage IIB Lung Cancer AJCC v8\|Stage IIIA Lung Cancer AJCC v8	May 29, 2020	Phase 2
NCT01656551	National Cancer Institute, Naples	Non-small Cell Lung Cancer Metastatic\|Non-small Cell Lung Cancer Stage IIIB	August 2012	Phase 3
NCT04164199	BeiGene	Advanced Malignancies	December 19, 2019	Phase 3
NCT00293579	Ohio State University Comprehensive Cancer Center	Head and Neck Cancer	February 2006	Phase 2
NCT04405674	Shanghai Chest Hospital	Non Small Cell Lung Cancer	July 15, 2020	Phase 2
NCT04619797	Hoffmann-La Roche	Non-small Cell Lung Cancer (NSCLC)	December 14, 2020	Phase 2\|Phase 3
NCT02486718	Hoffmann-La Roche	Non-Small Cell Lung Cancer	October 31, 2015	Phase 3
NCT03366766	Sidney Kimmel Cancer Center at Thomas Jefferson University\|Bristol-Myers Squibb\|Thomas Jefferson University	Non-Squamous Non-Small Cell Lung Carcinoma\|Stage I Non-Small Cell Lung Cancer\|Stage IA Non-Small Cell Lung Carcinoma\|Stage IB Non-Small Cell Lung Carcinoma\|Stage II Non-Small Cell Lung Cancer\|Stage IIA Non-Small Cell Lung Carcinoma\|Stage IIB Non-Small Cell Lung Carcinoma\|Stage IIIA Non-Small Cell Lung Cancer	December 20, 2017	Phase 2
NCT00111839	EMD Serono	Lung Cancer\|Non Small Cell Lung Carcinoma	May 31, 2005	Phase 2
NCT00320515	Eli Lilly and Company	Neoplasm, Gastric	March 2004	Phase 1\|Phase 2
NCT04222972	Hoffmann-La Roche	RET-fusion Non Small Cell Lung Cancer\|Lung Neoplasm\|Carcinoma, Non-Small-Cell Lung\|Respiratory Tract Neoplasms\|Thoracic Neoplasms\|Neoplasms by Site\|Neoplasms\|Lung Diseases\|Respiratory Tract Disease\|Carcinoma, Bronchogenic\|Bronchial Diseases\|Head and Neck Neoplasms\|Adenocarcinoma\|Carcinoma\|Neoplasms by Histologic Type\|Neoplasms, Germ Cell and Embryonal\|Neoplasms, Nerve Tissue	July 24, 2020	Phase 3
NCT04638582	McGill University Health Centre+Research Institute of the McGill University Health Centre	Lung Cancer, Nonsmall Cell	June 2021	Phase 2
NCT01828099	Novartis Pharmaceuticals\|Novartis	Non-Small Cell Lung Cancer	July 9, 2013	Phase 3
NCT00203931	University of Chicago\|Bristol-Myers Squibb	Non-small Cell Lung Cancer	March 2005	Phase 2
NCT05624996	NRG Oncology\|National Cancer Institute (NCI)	Locally Advanced Lung Non-Small Cell Carcinoma\|Stage IIB Lung Cancer AJCC v8\|Stage III Lung Cancer AJCC v8	June 9, 2023	Phase 3
NCT04211090	Sun Yat-sen University\|Jiangsu HengRui Medicine Co., Ltd.	Non-squamous Non-small-cell Lung Cancer\|Brain Metastases	January 15, 2020	Phase 2
NCT00418886	Genzyme, a Sanofi Company\|Sanofi	Non Small Cell Lung Cancer\|Lung Cancer	January 2007	Phase 3
NCT02337530	Canadian Cancer Trials Group\|AstraZeneca	Non-Small Cell Lung Cancer	February 5, 2015	Phase 2
NCT04459611	Second Affiliated Hospital, School of Medicine, Zhejiang University	Non-small Cell Lung Cancer	July 1, 2020	Phase 2
NCT00692159	Tracon Pharmaceuticals Inc.	Neoplasm	June 2008	Phase 1
NCT03498222	Queen Mary University of London\|Polaris Group\|Hoffmann-La Roche	Carcinoma, Non-Small-Cell Lung	June 1, 2018	Phase 1
NCT01126736	Eisai Inc.\|Quintiles, Inc.	Non Small Cell Lung Cancer	June 10, 2010	Phase 1\|Phase 2
NCT00606021	Eli Lilly and Company	Non Small Cell Lung Cancer	January 2008	Phase 2
NCT03744793	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant\|Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation\|Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation\|Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant\|Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant\|Metastatic Urothelial Carcinoma\|MTAP Negative	April 11, 2019	Phase 2
NCT00192088	Eli Lilly and Company	Advanced Gastric Carcinoma	May 2004	Phase 2
NCT02119650	Incyte Corporation	NSCLC (Non-small Cell Lung Carcinoma)	February 11, 2014	Phase 2
NCT03269162	lihegen\|Shanghai University of Traditional Chinese Medicine	NSCLC	September 30, 2016	Phase 3
NCT00227565	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Lung Cancer	February 2006	Phase 2
NCT05305885	The First Hospital of Jilin University\|The Second Hospital of Hebei Medical University\|Second Affiliated Hospital of Guangzhou Medical University\|The Affiliated Hospital of Guangdong Medical College\|Guangdong 999 Brain Hospital\|Wuxi People´s Hospital\|Huizhou Third People´s Hospital, Guangzhou Medical University\|Panjin Liaoyou Gem Flower Hospital	Leptomeningeal Metastasis	August 19, 2022	Not Applicable
NCT00227539	University of Washington\|National Cancer Institute (NCI)	Lung Cancer	July 2005	Phase 2
NCT03566576	Fujian Cancer Hospital	Non-squamous Non-small Cell Lung Cancer	July 1, 2018	Not Applicable
NCT00507858	M.D. Anderson Cancer Center\|Eli Lilly and Company	Head and Neck Cancer	September 2005	Phase 1
NCT03101579	The First Hospital of Jilin University	Leptomeningeal Metastases	March 1, 2017	Phase 1
NCT05011487	Sun Yat-sen University	Non-Small Cell Lung Cancer	August 13, 2021	Phase 2
NCT03912389	Biocad	Non-Squamous Non-Small Cell Neoplasm of Lung	June 1, 2019	Phase 3
NCT01907100	Boehringer Ingelheim	Mesothelioma	September 19, 2013	Phase 2\|Phase 3
NCT00440414	Hellenic Oncology Research Group\|University Hospital of Crete	Non Small Cell Lung Cancer	April 2006	Phase 3
NCT00988858	Eli Lilly and Company	Non Small Cell Lung Cancer	November 2009	Phase 2
NCT03866980	Akeso\|Akeso Tiancheng, Inc	Lung Cancer Non-small Cell Stage IV	November 27, 2018	Phase 3
NCT00079872	Eli Lilly and Company	Colorectal Cancer	February 2004	Phase 2
NCT00190762	Eli Lilly and Company	Mesothelioma	October 2001	Phase 3
NCT00402883	SCRI Development Innovations, LLC\|Genentech, Inc.\|Eli Lilly and Company	Lung Cancer	November 2006	Phase 2
NCT01215916	Eli Lilly and Company	Solid Tumors	February 2008	Phase 1
NCT00410904	National Cancer Institute (NCI)	Recurrent Non-small Cell Lung Cancer	October 2006	Phase 2
NCT01664754	Jonsson Comprehensive Cancer Center\|National Cancer Institute (NCI)	Stage IV Non-small Cell Lung Cancer	September 7, 2012	Phase 1
NCT03656549	Radboud University Medical Center\|ZonMw: The Netherlands Organisation for Health Research and Development	Non Small Cell Lung Cancer\|Mesothelioma	February 1, 2019	Phase 2
NCT00497315	University Hospital, Antwerp\|Universiteit Antwerpen\|Eli Lilly and Company	Non-Small Cell Lung Cancer	February 2006	Phase 2
NCT00349089	Thoraxklinik-Heidelberg gGmbH	Non Small Cell Lung Cancer	September 26, 2006	Phase 2
NCT02838745	Baylor College of Medicine	Mesothelioma	September 2016	Phase 1
NCT04989322	Dr Joanne CHIU\|The University of Hong Kong	Nsclc\|EGFR Activating Mutation\|EGF-R Positive Non-Small Cell Lung Cancer\|ALK Gene Rearrangement Positive\|ROS1 Gene Rearrangement\|ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung Cancer	October 5, 2021	Phase 2
NCT00350792	Eli Lilly and Company	Non Small Cell Lung Cancer	August 2006	Phase 2
NCT01263782	M.D. Anderson Cancer Center\|Eli Lilly and Company\|Genentech, Inc.	Lung Cancer	May 17, 2011	Phase 2
NCT00940069	Hunan Province Tumor Hospital	Non-small-cell Lung Cancer\|Adenocarcinoma	March 2009	Phase 2
NCT01004601	Chang Gung Memorial Hospital	Non Small Cell Lung Cancer	March 2005	Not Applicable
NCT03319537	Memorial Sloan Kettering Cancer Center\|M.D. Anderson Cancer Center	Mesothelioma	October 5, 2017	Phase 1\|Phase 2
NCT02037997	Fudan University	Non Small Cell Lung Cancer	December 2013	Phase 2
NCT00330915	Eli Lilly and Company	Rectal Neoplasms	June 2006	Phase 2
NCT05459441	Shanghai Pudong Hospital	Glioma\|Brain Metastases	January 1, 2022	Early Phase 1
NCT00070473	Children´s Oncology Group\|National Cancer Institute (NCI)	Unspecified Childhood Solid Tumor, Protocol Specific	October 2003	Phase 1
NCT05298423	Merck Sharp & Dohme LLC	Carcinoma, Non-Small-Cell Lung	May 3, 2022	Phase 3
NCT01840579	Merck Sharp & Dohme LLC	Solid Tumor\|Non-small Cell Lung Cancer\|Small Cell Lung Cancer	April 26, 2013	Phase 1
NCT05255302	Intergroupe Francophone de Cancerologie Thoracique	Metastatic NSCLC	May 2, 2022	Phase 2\|Phase 3
NCT03991403	Samsung Medical Center	Non-small Cell Lung Cancer	August 27, 2019	Phase 3
NCT04530227	Tianjin Medical University Cancer Institute and Hospital	Early Stage Non-small Cell Lung Cancer	September 25, 2020	Phase 2
NCT03636685	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	NSCLC\|Adenocarcinoma\|Squamous Cell Carcinoma	August 15, 2018	Phase 1\|Phase 2
NCT00799240	University of Kansas\|Merck Sharp & Dohme LLC\|University of Kansas Medical Center	Non Small Cell Lung Cancer	June 2009	Phase 2
NCT01064648	National Cancer Institute (NCI)	Epithelioid Mesothelioma\|Pleural Malignant Mesothelioma\|Recurrent Malignant Mesothelioma\|Sarcomatoid Mesothelioma	March 15, 2010	Phase 1\|Phase 2
NCT05059522	Pfizer	Advanced Malignancies\|NSCLC\|Ovarian Cancer\|Urothelial Cancer\|Solid Tumors	September 29, 2021	Phase 3
NCT05096663	Southwest Oncology Group\|National Cancer Institute (NCI)	Advanced Lung Non-Small Cell Carcinoma\|Recurrent Lung Non-Small Cell Carcinoma\|Stage III Lung Cancer AJCC v8\|Stage IIIA Lung Cancer AJCC v8\|Stage IIIB Lung Cancer AJCC v8\|Stage IIIC Lung Cancer AJCC v8\|Stage IV Lung Cancer AJCC v8\|Stage IVA Lung Cancer AJCC v8\|Stage IVB Lung Cancer AJCC v8	February 15, 2022	Phase 2\|Phase 3
NCT01646125	Novartis Pharmaceuticals\|Novartis	Advanced Non Small Cell Lung Cancer (NSCLC)	November 23, 2012	Phase 2
NCT00280748	UNC Lineberger Comprehensive Cancer Center\|National Cancer Institute (NCI)	Lung Cancer\|Metastatic Cancer	May 2005	Phase 2
NCT04794699	IDEAYA Biosciences	Solid Tumor	April 14, 2021	Phase 1
NCT04622007	Effector Therapeutics\|Medpace, Inc.	Non-small Cell Lung Cancer	June 2, 2021	Phase 2
NCT01105390	National Cancer Institute (NCI)	Advanced Malignant Mesothelioma\|Epithelial Mesothelioma\|Recurrent Malignant Mesothelioma\|Sarcomatous Mesothelioma	April 2010	Phase 2
NCT03819465	AstraZeneca	Metastatic Non-Small Cell Lung Cancer (NSCLC)	December 27, 2018	Phase 1
NCT05261399	AstraZeneca	Carcinoma\|Non-Small-Cell Lung	August 3, 2022	Phase 3
NCT03177291	H. Lee Moffitt Cancer Center and Research Institute	Lung Cancer\|Non Small Cell Lung Cancer\|Advanced Cancer\|Metastatic Lung Cancer\|Squamous Cell Lung Cancer\|Non-Squamous Non-Small Cell Neoplasm of Lung	September 26, 2017	Phase 1
NCT02200354	Kobe City General Hospital	Advanced Non-small Cell Lung Cancer	July 2014	Phase 2
NCT02013453	University of Michigan Rogel Cancer Center	Cancer of Head and Neck	December 2013	Phase 2
NCT03623776	Sun Yat-sen University	Efficacy and Safety	February 1, 2019	Phase 2
NCT00612677	H. Lee Moffitt Cancer Center and Research Institute\|Sanofi	Lung Cancer	June 2007	Phase 2
NCT01160744	Eli Lilly and Company	Carcinoma, Non-Small-Cell Lung	September 2010	Phase 2
NCT00251550	Eli Lilly and Company	Malignant Pleural Mesotherioma	October 2005	Phase 1\|Phase 2
NCT00886678	Zhejiang Cancer Hospital	Non-Small Cell Lung Cancer	July 2008	Phase 2
NCT04165070	Merck Sharp & Dohme LLC	Carcinoma, Non-Small-Cell Lung	December 19, 2019	Phase 2
NCT02145078	Barbara Ann Karmanos Cancer Institute\|National Cancer Institute (NCI)	Recurrent Non-small Cell Lung Cancer\|Stage IV Non-small Cell Lung Cancer	June 2014	Not Applicable
NCT00630149	Sun Yat-sen University\|Eli Lilly and Company	Nasopharyngeal Neoplasms	November 2007	Phase 2
NCT00577707	Memorial Sloan Kettering Cancer Center\|Genentech, Inc.	Non Small Cell Lung Cancer\|Lung Cancer	November 2007	Phase 2
NCT00061477	Eli Lilly and Company	Mesothelioma	December 2002	Phase 2
NCT02899299	Bristol-Myers Squibb\|Ono Pharmaceutical Co. Ltd	Mesothelioma	November 29, 2016	Phase 3
NCT01481259	People´s Hospital of Guangxi	Non-small Cell Lung Cancer	January 2010	Phase 2\|Phase 3
NCT01860040	Western Regional Medical Center	Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer\|Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer	April 2013	Phase 2
NCT00503997	Vanderbilt-Ingram Cancer Center\|National Cancer Institute (NCI)	Head and Neck Cancer	December 2006	Phase 2
NCT00923273	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Carcinoma, Non-Small-Cell Lung	February 29, 2008	Phase 1\|Phase 2
NCT03190239	Xinqiao Hospital of Chongqing	Advanced Non-squamous Non-small-cell Lung Cancer	July 15, 2017	Phase 2
NCT00573989	Wake Forest University Health Sciences\|National Cancer Institute (NCI)	Head and Neck Cancer	March 2008	Phase 1\|Phase 2
NCT01454934	Eisai Inc.	Non-Small Cell Lung Cancer (NSCLC)	December 9, 2011	Phase 3
NCT03626922	NSABP Foundation Inc\|Merck Sharp & Dohme LLC\|Eli Lilly and Company	Metastatic Colorectal Cancer	May 15, 2019	Phase 1
NCT03872661	Sun Yat-sen University	Lung Cancer Stage III	March 1, 2019	Phase 2
NCT03700333	The First Affiliated Hospital with Nanjing Medical University	Carcinoma, Non-Small-Cell Lung	October 20, 2018	Phase 3
NCT00129974	Tufts Medical Center\|Eli Lilly and Company	Carcinoma, Small Cell	August 2005	Phase 2
NCT00489359	Eli Lilly and Company	Ovarian Cancer\|Primary Peritoneal Cancer	July 2005	Phase 1\|Phase 2
NCT00005636	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Malignant Mesothelioma	November 1999	Phase 3
NCT04895735	Mayo Clinic\|National Cancer Institute (NCI)	Metastatic Salivary Gland Carcinoma\|Recurrent Salivary Gland Carcinoma\|Stage IV Major Salivary Gland Cancer AJCC v8\|Stage IVA Major Salivary Gland Cancer AJCC v8\|Stage IVB Major Salivary Gland Cancer AJCC v8\|Stage IVC Major Salivary Gland Cancer AJCC v8	July 23, 2021	Phase 2
NCT00497770	Eli Lilly and Company	Lung Neoplasms	February 2007
NCT00702299	University of Arizona\|National Cancer Institute (NCI)	Fallopian Tube Cancer\|Ovarian Cancer\|Peritoneal Cavity Cancer	September 2007	Phase 1
NCT05289908	The First Hospital of Jilin University\|The Affiliated Hospital of Guangdong Medical College\|Second Affiliated Hospital of Guangzhou Medical University\|Guangdong 999 Brain Hospital\|The Second Hospital of Hebei Medical University\|Panjin Liaoyou Gem Flower Hospital\|Wuxi People´s Hospital\|Huizhou Third People´s Hospital, Guangzhou Medical University	Leptomeningeal Metastases	February 21, 2022	Phase 1\|Phase 2
NCT00087113	Gynecologic Oncology Group\|National Cancer Institute (NCI)\|GOG Foundation	Cervical Cancer	August 2004	Phase 2
NCT02397928	NovoCure Ltd.	Malignant Pleural Mesothelioma	February 2015	Phase 2
NCT02194738	National Cancer Institute (NCI)	Lung Adenocarcinoma\|Lung Large Cell Carcinoma\|Resectable Lung Non-Small Cell Carcinoma\|Stage IB Lung Non-Small Cell Carcinoma AJCC v7\|Stage IB Lung Squamous Cell Carcinoma AJCC v7\|Stage II Lung Non-Small Cell Cancer AJCC v7\|Stage II Lung Squamous Cell Carcinoma AJCC v7\|Stage IIA Lung Non-Small Cell Carcinoma AJCC v7\|Stage IIA Lung Squamous Cell Carcinoma AJCC v7\|Stage IIB Lung Non-Small Cell Carcinoma AJCC v7\|Stage IIB Lung Squamous Cell Carcinoma AJCC v7\|Stage IIIA Lung Non-Small Cell Cancer AJCC v7\|Stage IIIA Lung Squamous Cell Carcinoma AJCC v7	August 18, 2014	Not Applicable
NCT04512430	Fundación GECP	Non Small Cell Lung Cancer\|EGFR Gene Mutation	December 2, 2020	Phase 2
NCT00191308	Eli Lilly and Company	Non-Small Cell Lung Cancer\|Carcinoma	May 2005	Phase 2
NCT05469178	BerGenBio ASA	Carcinoma, Non-Small-Cell Lung	October 2022	Phase 1\|Phase 2
NCT01868022	GlaxoSmithKline	Neoplasms	October 9, 2013	Phase 1
NCT02947113	The Netherlands Cancer Institute	Non-Small Cell Lung Cancer	November 2017	Phase 2
NCT04367311	Nasser Hanna\|Genentech, Inc.\|Big Ten Cancer Research Consortium	Lung Cancer\|NSCLC	May 22, 2020	Phase 2
NCT05104788	Peking University Cancer Hospital & Institute	Non-Small Cell Lung Cancer	October 25, 2021	Phase 2
NCT01445392	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Mesothelioma	November 14, 2007	Phase 1
NCT02609776	Janssen Research & Development, LLC	Non-Small-Cell Lung Cancer	May 24, 2016	Phase 1
NCT03489616	Shandong Cancer Hospital and Institute	Carcinoma, Non-Small-Cell Lung	January 15, 2018	Not Applicable
NCT00506051	Genzyme, a Sanofi Company\|Sanofi	Carcinoma\|Non-Small Cell Lung\|Lung Cancer	July 2005	Phase 1
NCT04786964	Checkpoint Therapeutics, Inc.	Metastatic Non-squamous Non Small Cell Lung Cancer	December 8, 2021	Phase 3
NCT00316225	Eli Lilly and Company	Non-small Cell Lung Cancer\|Mesothelioma\|Lung Neoplasms	December 2006	Phase 2
NCT00102219	Eli Lilly and Company	Breast Cancer	October 2004	Phase 2
NCT04047862	BeiGene	Locally Advanced and Metastatic Solid Tumors	August 26, 2019	Phase 1
NCT03337698	Hoffmann-La Roche	Carcinoma, Non-Small-Cell Lung	January 2, 2018	Phase 1\|Phase 2
NCT01953419	Sun Yat-sen University	Gastric Cancer	September 2010	Phase 2
NCT00700336	CanBas Co. Ltd.	Malignant Pleural Mesothelioma\|Solid Tumors	May 2008	Phase 1\|Phase 2
NCT01783834	Gachon University Gil Medical Center	Previous Treated Metastatic Non-small Cell Lung Cancer	February 2008	Phase 2
NCT00402051	Eli Lilly and Company	Non-Small-Cell Lung Cancer	November 2006	Phase 2
NCT02723955	GlaxoSmithKline\|Merck Sharp & Dohme LLC	Neoplasms	June 23, 2016	Phase 1
NCT05132413	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer	December 30, 2021	Phase 3
NCT02488694	AIO-Studien-gGmbH\|Boehringer Ingelheim	Non-small-cell Lung Cancer With Somatic EGFR Mutations	November 2015	Phase 2
NCT04695925	Li Zhang, MD\|Sun Yat-sen University	Non-small Cell Carcinoma\|EGFR Gene Mutation	January 4, 2021	Phase 3
NCT05258279	Juntendo University\|Merck Sharp & Dohme LLC	Non-squamous Non-small-cell Lung Cancer\|EGFR Activating Mutation	July 2022	Phase 2
NCT02220894	Merck Sharp & Dohme LLC	Non-small Cell Lung Cancer	October 30, 2014	Phase 3
NCT00402766	M.D. Anderson Cancer Center\|Novartis	Mesothelioma	August 2006	Phase 1
NCT04265534	Calithera Biosciences, Inc	Non-Small Cell Lung Cancer\|Non-squamous Non-small-cell Lung Cancer\|Non-Squamous Non-Small Cell Neoplasm of Lung\|KEAP1 Gene Mutation\|NRF2 Gene Mutation\|NFE2L2 Gene Mutation	July 24, 2020	Phase 2
NCT03920839	Incyte Corporation	Advanced and+or Metastatic Solid Tumors\|Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer\|Advanced+Metastatic Unresectable Malignant Pleural Mesothelioma	July 15, 2019	Phase 1
NCT00494026	Eli Lilly and Company	Small Cell Lung Cancer	September 2007	Phase 2
NCT03875144	Institut du Cancer de Montpellier - Val d´Aurelle	Peritoneal Mesothelioma\|Peritoneal Carcinomatosis	August 14, 2020	Phase 2
NCT04162015	Memorial Sloan Kettering Cancer Center\|Bristol-Myers Squibb	Malignant Pleural Mesothelioma	November 12, 2019	Phase 1
NCT00738582	Morphotek	Malignant Pleural Mesothelioma	December 31, 2008	Phase 2
NCT02076477	Sichuan Cancer Hospital and Research Institute\|Mianyang Central Hospital\|Cancer Hospital of Guizhou Province	Oligo-metastatic Stage IV Non-small Cell Lung Cancer	January 2014	Phase 3
NCT01169675	Boehringer Ingelheim	Neoplasms	July 2010	Phase 1
NCT04846452	The First Affiliated Hospital with Nanjing Medical University	Metastatic NSCLC\|Recurrent NSCLC\|Advanced Non-Small Cell Squamous Lung Cancer	June 1, 2021	Phase 2
NCT00190671	Eli Lilly and Company	Breast Cancer	June 2005	Phase 1\|Phase 2
NCT04623775	Bristol-Myers Squibb	Non-small Cell Lung Cancer\|Recurrent Non-small Cell Lung Cancer\|Metastatic Non-small Cell Lung Cancer	February 17, 2021	Phase 2
NCT05335941	M.D. Anderson Cancer Center	Urothelial Carcinoma\|Metastatic Cancer	September 30, 2022	Phase 2
NCT01313663	GlaxoSmithKline	Lung Cancer, Small Cell	February 2011	Phase 2
NCT00517595	Accelerated Community Oncology Research Network\|Eli Lilly and Company\|Genentech, Inc.	Non-Small Cell Lung Cancer	August 2007	Phase 2
NCT03085914	Incyte Corporation	Solid Tumor	May 2, 2017	Phase 1\|Phase 2
NCT00415636	Eli Lilly and Company	Cancer	January 2007	Phase 1
NCT01338792	University of Southern California\|National Cancer Institute (NCI)	Hormone-resistant Prostate Cancer\|Recurrent Prostate Cancer	June 2006	Phase 2
NCT01655225	Eli Lilly and Company	Advanced Cancer\|Metastatic Cancer\|Non-Hodgkin´s Lymphoma\|Metastatic Breast Cancer\|Malignant Mesothelioma\|Non-small Cell Lung Cancer	July 31, 2012	Phase 1
NCT01041781	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Lung Cancer	February 2010	Phase 3
NCT03846310	Arcus Biosciences, Inc.\|Gilead Sciences	Non Small Cell Lung Cancer Metastatic\|Non Small Cell Lung Cancer\|Nonsquamous Nonsmall Cell Neoplasm of Lung\|Sensitizing EGFR Gene Mutation	April 1, 2019	Phase 1
NCT00078260	Eli Lilly and Company	Non-Small Cell Lung Cancer	December 2003	Phase 3
NCT01165021	Eli Lilly and Company	Non Small Cell Lung Cancer	November 2010	Phase 2
NCT03215706	Bristol-Myers Squibb	Non-Small Cell Lung Cancer	August 24, 2017	Phase 3
NCT00117962	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)\|Eli Lilly and Company\|Bristol-Myers Squibb	Lung Cancer	September 2005	Phase 2
NCT00786552	University Hospital Schleswig-Holstein	Thyroid Cancer	November 2008	Phase 2
NCT05364645	Southwest Oncology Group\|National Cancer Institute (NCI)	Lung Non-Small Cell Carcinoma\|Recurrent Lung Non-Small Cell Carcinoma\|Stage IV Lung Cancer AJCC v8\|Stage IVA Lung Cancer AJCC v8\|Stage IVB Lung Cancer AJCC v8	July 25, 2022	Phase 2
NCT01087970	Eli Lilly and Company	Head and Neck Neoplasms	August 2010	Phase 2
NCT00660816	Case Comprehensive Cancer Center\|National Cancer Institute (NCI)	Lung Cancer	January 2008	Phase 2
NCT04647344	Akeso	Lung Cancer Non-Small Cell Stage IIIB+IIIC+IV	November 24, 2020	Phase 1\|Phase 2
NCT00979576	Boehringer Ingelheim	Carcinoma, Non-Small-Cell Lung	October 2009	Phase 1
NCT03110484	Samsung Medical Center	Biliary Tract Cancer	July 9, 2021	Phase 2
NCT00715611	Memorial Sloan Kettering Cancer Center\|M.D. Anderson Cancer Center\|Princess Margaret Hospital, Canada\|Mayo Clinic\|Brigham and Women´s Hospital	Mesothelioma	October 11, 2008	Phase 2
NCT00268489	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Lung Cancer	May 2006	Phase 2
NCT00269152	Eli Lilly and Company	Non-Small Cell Lung Cancer	December 2005	Phase 2
NCT03987867	Tianjin Medical University Cancer Institute and Hospital	Non-small Cell Lung Cancer\|First-line Treatment	June 1, 2019	Phase 1
NCT05611879	Beijing Tsinghua Chang Gung Hospital	NSCLC, Stage III	November 1, 2022	Phase 2
NCT00193414	SCRI Development Innovations, LLC\|Eli Lilly and Company	Lung Cancer	May 2005	Phase 2
NCT00291707	University of Pittsburgh\|Eli Lilly and Company\|Bristol-Myers Squibb	Head and Neck Cancer	March 2006	Phase 1
NCT04533451	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Metastatic Lung Adenocarcinoma\|Metastatic Lung Non-Small Cell Carcinoma\|Recurrent Lung Adenocarcinoma\|Recurrent Lung Non-Small Cell Carcinoma\|Stage IV Lung Cancer AJCC v8\|Stage IVA Lung Cancer AJCC v8\|Stage IVB Lung Cancer AJCC v8	October 1, 2020	Phase 2
NCT01376310	Novartis Pharmaceuticals\|Novartis	Cancer	November 2, 2010	Phase 2
NCT00226577	H. Lee Moffitt Cancer Center and Research Institute\|National Cancer Institute (NCI)\|Eli Lilly and Company	Lung Cancer	February 2004	Phase 2
NCT05403385	iTeos Belgium SA\|iTeos Therapeutics	Metastatic NSCLC\|Stage III NSCLC	August 26, 2022	Phase 2
NCT01143974	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Locally Advanced Malignant Neoplasm	June 2010	Phase 4
NCT00907179	University of Pittsburgh\|Novartis Pharmaceuticals	Non-Small Cell Lung Cancer	July 2009	Phase 1
NCT00487669	Dartmouth-Hitchcock Medical Center\|CTI BioPharma	Advanced Non-small Cell Lung Cancer	October 2006	Phase 2
NCT02595840	Universität Duisburg-Essen	Non-small-cell Lung Cancer With Somatic EGFR Mutations	November 25, 2015	Phase 2
NCT03655821	Radboud University Medical Center\|ZonMw: The Netherlands Organisation for Health Research and Development	Non Small Cell Lung Cancer\|Mesothelioma	February 1, 2019	Phase 4
NCT01666977	Amgen	Non Small Cell Lung Cancer	August 2012	Phase 1\|Phase 2
NCT02657434	Hoffmann-La Roche	Non-Small Cell Lung Cancer	April 30, 2016	Phase 3
NCT00619424	GlaxoSmithKline	Lung Cancer, Non-Small Cell	November 15, 2007	Phase 1
NCT05498428	Janssen Research & Development, LLC	Carcinoma, Non-small-Cell Lung	December 2, 2022	Phase 2
NCT05281406	Goethe University	NSCLC Stage IIIB\|NSCLC Stage IV	November 12, 2021	Phase 2
NCT02211833	Boehringer Ingelheim	Carcinoma, Non-Small-Cell Lung	October 2006	Phase 1
NCT04988295	Janssen Research & Development, LLC	Carcinoma, Non-Small-Cell Lung	November 17, 2021	Phase 3
NCT03976323	Merck Sharp & Dohme LLC	Carcinoma, Non-squamous Non-small-cell Lung	June 28, 2019	Phase 3
NCT04943627	Agenus Inc.\|European Network of Gynaecological Oncological Trial Groups (ENGOT)	Advanced Cancer\|Metastatic Cervical Cancer	August 2, 2021	Phase 3
NCT03952403	Shanghai Henlius Biotech	Carcinoma\|Non-Small-Cell Lung	December 2, 2019	Phase 3
NCT02574078	Bristol-Myers Squibb	Non-Small Cell Lung Cancer	November 23, 2015	Phase 1\|Phase 2
NCT03396445	Merck Sharp & Dohme LLC	Pharmacokinetics\|Solid Tumor\|Carcinoma, Non-Small-Cell Lung\|Triple Negative Breast Neoplasms	February 18, 2018	Phase 1
NCT05298176	Amsterdam UMC, location VUmc	Non-Small Cell Lung Cancer	January 4, 2022	Phase 2
NCT01631136	Intergroupe Francophone de Cancerologie Thoracique\|Groupe Francais De Pneumo-Cancerologie	Advanced Non Small Cell Lung Cancer	July 2012	Phase 3
NCT00234052	Northwestern University\|National Cancer Institute (NCI)	Lung Cancer	July 28, 2005	Phase 2
NCT02409342	Hoffmann-La Roche	Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer	July 20, 2015	Phase 3
NCT00489983	Eli Lilly and Company	Non-Small Cell Lung Cancer	July 2003	Phase 2
NCT00701857	University of Arizona\|National Cancer Institute (NCI)	Esophageal Cancer	February 2008	Phase 1
NCT00994097	AGC Biologics S.p.A.	Non-small Cell Lung Cancer	July 2009	Phase 2
NCT03950674	Merck Sharp & Dohme LLC	Non-Small-Cell Lung Carcinoma	February 22, 2016	Phase 3
NCT04736823	Akeso	NSCLC	February 1, 2021	Phase 2
NCT02274038	University of Pennsylvania	Non-small Cell Lung Cancer\|Starting Pemetrexed Based Therapy\|Unresectable Cancer	March 2015	Not Applicable
NCT04372927	University of Washington\|AstraZeneca	Locally Advanced Lung Non-Small Cell Carcinoma\|Stage III Lung Cancer AJCC v8\|Stage IIIA Lung Cancer AJCC v8\|Stage IIIB Lung Cancer AJCC v8\|Stage IIIC Lung Cancer AJCC v8	December 10, 2021	Phase 2
NCT02669719	Shanghai Chest Hospital\|SOTIO a.s.	Non Small Cell Lung Cancer	January 2016	Phase 2
NCT05209620	Henan Cancer Hospital	Central Nervous System Lymphoma	December 21, 2021	Phase 2
NCT00102804	Eli Lilly and Company	Non-Small Cell Lung Cancer	March 2005	Phase 3
NCT01553942	Massachusetts General Hospital	Lung Cancer	April 2012	Phase 2
NCT03003962	AstraZeneca	Non Small Cell Lung Carcinoma NSCLC	January 2, 2017	Phase 3
NCT00835471	Dutch Society of Physicians for Pulmonology and Tuberculosis	Carcinoma, Non-Small-Cell Lung	March 2009	Phase 2
NCT00087087	Gynecologic Oncology Group\|National Cancer Institute (NCI)\|Eli Lilly and Company\|GOG Foundation	Ovarian Cancer\|Primary Peritoneal Cavity Cancer	July 2004	Phase 2
NCT02974933	Wuling Ou\|Jiangsu HengRui Medicine Co., Ltd.\|Hubei Clinical Research Collaboration Group\|Hubei Cancer Hospital	Nonsmall Cell Lung Cancer	November 2016	Phase 2
NCT00216216	Hoosier Cancer Research Network\|Eli Lilly and Company\|Walther Cancer Institute	Small Cell Lung Cancer	January 2005	Phase 2
NCT00061464	Eli Lilly and Company	Carcinoma, Non-Small-Cell Lung	February 2003	Phase 2
NCT00762034	Eli Lilly and Company	Non-small Cell Lung Cancer	December 2008	Phase 3
NCT04706949	Fudan University	Lung Cancer, Non-small Cell	December 7, 2020	Phase 2
NCT02604342	Hoffmann-La Roche	Non-small Cell Lung Cancer	November 3, 2015	Phase 3
NCT04220892	Jose Carrillo\|Eli Lilly and Company\|Saint John´s Cancer Institute	High Grade Glioma	July 8, 2020	Early Phase 1
NCT00106002	Eli Lilly and Company	Breast Cancer\|Breast Neoplasms, Male\|Carcinoma, Ductal	April 2005	Phase 2
NCT04205812	Incyte Corporation\|Zai Lab (Shanghai) Co., Ltd.	Metastatic Squamous Non-Small Cell Lung Cancer\|Metastatic Nonsquamous Non-Small Cell Lung Cancer	September 27, 2020	Phase 3
NCT01344824	UNC Lineberger Comprehensive Cancer Center\|National Cancer Institute (NCI)	Lung Cancer	March 2010	Phase 2
NCT03829319	Merck Sharp & Dohme LLC\|Eisai Inc.	Nonsquamous Non-small Cell Lung Cancer	March 25, 2019	Phase 3
NCT00454649	Pfizer	Neoplasms	December 2005	Phase 1
NCT00415194	Eli Lilly and Company	Head and Neck Neoplasms	December 2006	Phase 3
NCT04991025	Memorial Sloan Kettering Cancer Center	Lung Cancer\|Lung Cancer Stage II\|Lung Cancer Stage III	October 19, 2022	Phase 2
NCT00545948	Duke University\|Eli Lilly and Company	Carcinoma, Non-Small-Cell Lung	December 2007	Phase 2
NCT00087698	Eli Lilly and Company	Pleural Neoplasms	September 2003	Phase 2
NCT03631784	Merck Sharp & Dohme LLC	Non-small Cell Lung Cancer	October 19, 2018	Phase 2
NCT02426658	Wake Forest University Health Sciences\|National Cancer Institute (NCI)	Stage IV Non-Small Cell Lung Cancer	May 2015	Phase 2
NCT03134872	Jiangsu HengRui Medicine Co., Ltd.	Lung Neoplasms\|Carcinoma, Non-Small-Cell Lung\|Respiratory Tract Neoplasms\|Thoracic Neoplasms\|Lung Diseases\|Respiratory Tract Disease\|Neoplasms by Site\|Neoplasm, Bronchial\|Carcinoma, Bronchogenic	May 12, 2017	Phase 3
NCT01005680	Eli Lilly and Company	Non Small Cell Lung Cancer	November 2009	Phase 3
NCT04750083	Taizhou Hanzhong biomedical co. LTD	Nonsquamous Non-small Cell Lung Cancer	September 25, 2020	Phase 2\|Phase 3
NCT03432598	BeiGene	Locally Advanced Lung Cancer; Metastatic Lung Cancer	August 24, 2017	Phase 2
NCT04077463	Janssen Research & Development, LLC	Carcinoma, Non-Small-Cell Lung	September 4, 2019	Phase 1
NCT01004250	Eli Lilly and Company	Non-Small Cell Lung Cancer	October 2009	Phase 2
NCT04929041	National Cancer Institute (NCI)	Advanced Lung Adenocarcinoma\|Advanced Lung Adenosquamous Carcinoma\|Advanced Lung Non-Small Cell Carcinoma\|Metastatic Lung Adenocarcinoma\|Metastatic Lung Adenosquamous Carcinoma\|Metastatic Lung Non-Small Cell Carcinoma\|Stage IIIB Lung Cancer AJCC v8\|Stage IIIC Lung Cancer AJCC v8\|Stage IV Lung Cancer AJCC v8\|Stage IVA Lung Cancer AJCC v8\|Stage IVB Lung Cancer AJCC v8	December 21, 2021	Phase 2\|Phase 3
NCT01442909	Taipei Veterans General Hospital, Taiwan	Non-small-cell Lung Cancer	March 2008	Phase 4
NCT03460678	Hikma Pharmaceuticals LLC	Carcinoma, Non-Small-Cell Lung	February 28, 2018	Phase 4
NCT02631460	Sun Yat-sen University	NSCLC	December 2015	Phase 2
NCT00438204	Barbara Ann Karmanos Cancer Institute\|National Cancer Institute (NCI)	Lung Cancer	May 2006	Phase 2
NCT05226598	Merck Sharp & Dohme LLC	Metastatic Non-Small Cell Lung Cancer	March 24, 2022	Phase 3
NCT04964960	John L. Villano, MD, PhD\|University of Kentucky	Lung Cancer\|Lung Cancer Metastatic\|Brain Cancer\|Cancer	December 7, 2021	Phase 2
NCT01982955	Merck KGaA, Darmstadt, Germany	Non-small Cell Lung Cancer	December 23, 2013	Phase 1\|Phase 2
NCT04500717	Cancer Institute and Hospital, Chinese Academy of Medical Sciences\|Jiangsu Hansoh Pharmaceutical Co., Ltd.	Non Small Cell Lung Cancer	October 2020	Phase 3
NCT00560573	Pfizer	Carcinoma, Non-Small-Cell Lung	November 2007	Phase 1
NCT04025879	Bristol-Myers Squibb	Carcinoma, Non-Small-Cell Lung	November 5, 2019	Phase 3
NCT03062800	Qilu Hospital of Shandong University	Advanced Nsclc	December 2016	Phase 2
NCT02031601	Qilu Hospital of Shandong University	Non-Small-Cell Lung Cancer	January 2014	Phase 4
NCT00281125	Nevada Cancer Institute	Non-Small Cell Lung Cancer and Pleural Mesothelioma	January 2006	Phase 1\|Phase 2
NCT04507217	Sun Yat-sen University	NSCLC Stage IV\|Brain Metastases\|PD-1 Antibody	September 1, 2020	Phase 2
NCT01809210	AstraZeneca	Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV	April 4, 2013	Phase 1
NCT00538681	Eli Lilly and Company	Lung Cancer	September 2007	Phase 2
NCT01192243	Fudan University	Toxicity\|Non-small Cell Lung Cancer	December 2009	Phase 2
NCT00324805	National Cancer Institute (NCI)\|Cancer and Leukemia Group B\|NCIC Clinical Trials Group\|North Central Cancer Treatment Group\|Southwest Oncology Group	Stage IB Lung Non-Small Cell Carcinoma AJCC v7\|Stage IIA Lung Non-Small Cell Carcinoma AJCC v7\|Stage IIB Lung Non-Small Cell Carcinoma AJCC v7\|Stage IIIA Lung Non-Small Cell Cancer AJCC v7	June 1, 2007	Phase 3
NCT03520686	ImmunityBio, Inc.	Non Small Cell Lung Cancer	May 18, 2018	Phase 3
NCT04054531	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	Non-small Cell Lung Cancer	September 4, 2019	Phase 2
NCT00251524	Veeda Oncology\|Sanofi\|Eli Lilly and Company\|Genentech, Inc.	Non-Small Cell Lung Cancer	November 2005	Phase 2
NCT00520676	Eli Lilly and Company	Non-Small Cell Lung Cancer	October 2007	Phase 3
NCT01172028	University of Arizona\|National Cancer Institute (NCI)	Breast Cancer\|Esophageal Cancer\|Gastric Cancer\|Head and Neck Cancer\|Lung Cancer\|Ovarian Cancer\|Prostate Cancer	September 2005	Phase 1
NCT00216203	Nasser Hanna, M.D.\|Eli Lilly and Company\|Bristol-Myers Squibb\|Walther Cancer Institute\|Hoosier Cancer Research Network	Non-Small Cell Lung Cancer	May 2005	Phase 1\|Phase 2
NCT02477826	Bristol-Myers Squibb\|Ono Pharmaceutical Co. Ltd	Non-Small Cell Lung Cancer	August 5, 2015	Phase 3
NCT02284490	Rongjie Tao\|National Natural Science Foundation of China\|Shandong Cancer Hospital and Institute	Brain Metastases	November 2014	Phase 2
NCT00387322	University of California, Davis\|National Cancer Institute (NCI)	Lung Cancer\|Unspecified Adult Solid Tumor, Protocol Specific	March 2005	Phase 1\|Phase 2
NCT05047250	Hoffmann-La Roche	Non-Small Cell Lung Cancer	June 15, 2022	Phase 3
NCT04410796	Memorial Sloan Kettering Cancer Center\|AstraZeneca\|GUARDANT HEALTH	Metastatic Non-small Cell Lung Cancer	May 28, 2020	Phase 2
NCT04267848	National Cancer Institute (NCI)	Lung Non-Small Cell Carcinoma\|Lung Non-Small Cell Squamous Carcinoma\|Lung Non-Squamous Non-Small Cell Carcinoma\|Stage II Lung Cancer AJCC v8\|Stage IIA Lung Cancer AJCC v8\|Stage IIB Lung Cancer AJCC v8\|Stage IIIA Lung Cancer AJCC v8\|Stage IIIB Lung Cancer AJCC v8	June 3, 2020	Phase 3
NCT00871403	GlaxoSmithKline	Lung Cancer, Non-Small Cell	July 2009	Phase 2
NCT00903292	National Cheng-Kung University Hospital	Non-Small Cell Lung Cancer	March 2009	Not Applicable
NCT03840915	EMD Serono Research & Development Institute, Inc.\|Merck KGaA, Darmstadt, Germany\|EMD Serono	Carcinoma, Non-Small-Cell Lung	April 2, 2019	Phase 1\|Phase 2
NCT03064854	Novartis Pharmaceuticals\|Novartis	Non-small Cell Lung Cancer	May 24, 2017	Phase 1
NCT04262869	Emory University\|National Cancer Institute (NCI)	Lung Non-Small Cell Carcinoma\|Stage IIIB Lung Cancer AJCC v8\|Stage IV Lung Cancer AJCC v8\|Stage IVA Lung Cancer AJCC v8\|Stage IVB Lung Cancer AJCC v8	March 27, 2020	Phase 2
NCT04836728	Tianjin Medical University Cancer Institute and Hospital	Non-small Cell Lung Cancer Metastatic\|First-line Treatment	April 1, 2021	Phase 2
NCT01569919	Wales Cancer Trials Unit\|Velindre NHS Trust\|June Hancock Mesothelioma Research Fund\|Velindre Cancer Centre Stepping Stones Appeal	Malignant\|Pleural\|Mesothelioma	December 2012	Phase 2
NCT01454102	Bristol-Myers Squibb	Non-small Cell Lung Cancer	December 16, 2011	Phase 1
NCT02787473	First People´s Hospital of Hangzhou	Squamous Cell Lung Cancer	October 2016	Phase 2
NCT00290017	Point Therapeutics	Carcinoma, Non-Small-Cell Lung\|Lung Cancer\|Neoplasms, Lung\|Neoplasms, Pulmonary	February 2006	Phase 3
NCT04686305	AstraZeneca\|Daiichi Sankyo, Inc.	Locally Advanced or Metastatic Non-Small Cell Lung Cancer	March 9, 2021	Phase 1
NCT01496742	Genentech, Inc.	Non-Squamous Non-Small Cell Lung Cancer	April 2012	Phase 2
NCT05136677	Bristol-Myers Squibb	Mesothelioma, Malignant	January 25, 2022	Phase 2
NCT00191412	Eli Lilly and Company	Liver Cancer	January 2005	Phase 2
NCT04861948	Innovent Biologics (Suzhou) Co. Ltd.	Solid Tumors\|Lung Adenocarcinoma\|Osteosarcoma	May 25, 2021	Phase 1
NCT00106626	Merck Sharp & Dohme LLC	Advanced Cancer	August 2005	Phase 1
NCT02794571	Genentech, Inc.	Advanced+Metastatic Tumors	May 23, 2016	Phase 1
NCT02531854	Advaxis, Inc.	Carcinoma, Non-Small-Cell Lung	December 2016	Phase 2
NCT02639091	Bayer	Medical Oncology	February 3, 2016	Phase 1
NCT02862457	Merck Sharp & Dohme LLC	Neoplasms\|Carcinoma, Non-Small-Cell Lung	August 23, 2016	Phase 1
NCT01705184	Intergroupe Francophone de Cancerologie Thoracique	Non-small Cell Lung Cancer Metastatic\|Nonsquamous Nonsmall Cell Neoplasm of Lung	December 2012	Phase 2
NCT00320073	UNC Lineberger Comprehensive Cancer Center\|National Cancer Institute (NCI)	Unspecified Adult Solid Tumor, Protocol Specific	August 2006	Phase 1
NCT00741221	Hellenic Oncology Research Group	Non-small-cell Lung Cancer	June 2008	Phase 2
NCT00891579	Chinese Society of Lung Cancer	Non Small Cell Lung Cancer	February 2009	Phase 2
NCT02148380	Baohui Han\|Shanghai Chest Hospital	Non-Small-Cell Lung Cancer	May 2014	Not Applicable
NCT03233139	Regeneron Pharmaceuticals	Advanced Malignancies	June 21, 2017	Phase 1
NCT00867009	Eli Lilly and Company	Non-Small-Cell Lung Cancer	April 2009	Phase 2
NCT03802240	Innovent Biologics (Suzhou) Co. Ltd.	Non-Squamous Non-Small Cell Lung Cancer	July 11, 2019	Phase 3
NCT01020786	Eli Lilly and Company	Non Small Cell Lung Cancer	November 2009	Phase 4
NCT00614822	Christiana Care Health Services\|Eli Lilly and Company	Non Small Cell Lung Cancer	November 2007	Phase 2
NCT00095199	Eli Lilly and Company	Non Small Cell Lung Cancer	January 2005	Phase 3
NCT04422392	Shanghai Pulmonary Hospital, Shanghai, China	Non Small Cell Lung Cancer	July 13, 2020	Phase 2
NCT04194944	Loxo Oncology, Inc.\|Eli Lilly and Company	Non-Small Cell Lung Cancer	February 17, 2020	Phase 3
NCT04203511	Incyte Corporation	Non-small Cell Lung Cancer	July 31, 2020	Phase 3
NCT01928160	Vanderbilt-Ingram Cancer Center\|National Cancer Institute (NCI)	Recurrent Non-small Cell Lung Cancer\|Stage IV Non-small Cell Lung Cancer	June 2014	Phase 2
NCT01836575	Instituto Nacional de Cancer, Brazil\|Eli Lilly and Company	Non Small Cell Lung Carcinoma	April 2008	Phase 3
NCT02579564	Xinqiao Hospital of Chongqing	Malignant Hydrothorax\|Non Small Cell Lung Cancer	October 2016	Phase 3
NCT05456256	Lantern Pharma Inc.	Adenocarcinoma of Lung\|Carcinoma, Non-Small-Cell Lung	August 12, 2022	Phase 2
NCT02296671	Washington University School of Medicine\|Gateway for Cancer Research	Esophagogastric Cancer	February 2015	Phase 2
NCT01401192	Samsung Medical Center	Non-small Cell Lung Cancer	July 2011	Phase 2
NCT00101283	Eastern Cooperative Oncology Group\|National Cancer Institute (NCI)\|North Central Cancer Treatment Group	Mesothelioma	November 2005	Phase 2
NCT00573690	UNC Lineberger Comprehensive Cancer Center\|National Cancer Institute (NCI)	Unspecified Adult Solid Tumor, Protocol Specific	September 2007	Phase 1
NCT00789373	Eli Lilly and Company	Non-Small Cell Lung Cancer	November 2008	Phase 3
NCT01000480	Eli Lilly and Company	Non Small Cell Lung Cancer	October 2009	Phase 2
NCT04396457	National Hospital Organization Nagoya Medical Center\|Central Japan Lung Study Group\|Merck Sharp & Dohme LLC	Non-squamous Non-small-cell Lung Cancer\|Cancer, Lung	May 25, 2020	Phase 2
NCT04843007	NanoAlvand	Non Small Cell Lung Cancer\|Malignant Pleural Mesothelioma	October 5, 2016
NCT00034606	Eli Lilly and Company	Carcinoma, Non-Small-Cell Lung\|Lung Neoplasms\|Neoplasms		Phase 2
NCT01085630	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Malignant Mesothelioma	April 2010	Phase 2
NCT00383331	Eli Lilly and Company	Non-Small-Cell Lung Cancer	February 2007	Phase 2
NCT00530621	Eli Lilly and Company	Non-small Cell Lung Cancer	September 2007	Phase 2
NCT00061451	Eli Lilly and Company	Carcinoma, Non-Small-Cell Lung	December 2002	Phase 2
NCT00434174	Novartis Pharmaceuticals\|Novartis	Non Small Cell Lung Cancer	December 2006	Phase 1
NCT02784171	Canadian Cancer Trials Group\|National Cancer Institute, Naples\|Merck Sharp & Dohme LLC\|Intergroupe Francophone de Cancerologie Thoracique	Mesothelioma	October 7, 2016	Phase 2\|Phase 3
NCT00921310	Washington University School of Medicine	Carcinoma, Non-Small-Cell Lung	September 2009	Phase 1\|Phase 2
NCT00087711	Eli Lilly and Company	Non Small Cell Lung Carcinoma	July 2004	Phase 3
NCT05502237	Gilead Sciences\|Arcus Biosciences, Inc.	Non-small Cell Lung Cancer	October 12, 2022	Phase 3
NCT03178552	Hoffmann-La Roche	Non-Small Cell Lung Cancer	September 22, 2017	Phase 2\|Phase 3
NCT03768037	Guangdong Association of Clinical Trials	Advanced Non-squamous NSCLC	November 26, 2018	Phase 4
NCT00369629	Northwestern University\|National Cancer Institute (NCI)\|Eli Lilly and Company	Lymphoma	August 28, 2006	Phase 1
NCT03792503	Xinqiao Hospital of Chongqing	Advanced Non-squamous Non-small-cell Lung Cancer	February 2019	Phase 4
NCT00053209	Eastern Cooperative Oncology Group\|National Cancer Institute (NCI)	Bladder Cancer\|Transitional Cell Cancer of the Renal Pelvis and Ureter\|Urethral Cancer	April 2004	Phase 2
NCT01373463	Medical University of South Carolina	Nonsquamous Nonsmall Cell Neoplasm of Lung\|Nonsmall Cell Lung Cancer Stage III	May 2011	Phase 1
NCT05015608	Hutchison Medipharma Limited\|Hutchmed	Non-small Cell Lung Cancer	November 22, 2021	Phase 3
NCT00982111	Eli Lilly and Company\|Quintiles, Inc.\|Parexel\|PPD\|Medidata Solutions\|Laboratory Corporation of America\|University of Colorado, Denver\|Thermo Fisher Scientific, Inc\|Pacific Biomarkers\|Intertek\|Sysmex Inostics GmbH	Non Small Cell Lung Cancer	November 2, 2009	Phase 3
NCT02743923	The Netherlands Cancer Institute\|Dutch Society of Physicians for Pulmonology and Tuberculosis	Carcinoma, Non-Small Cell Lung	April 2016	Phase 3
NCT02162537	Centre Hospitalier Intercommunal Creteil\|Groupe Francais De Pneumo-Cancerologie	Non-small Cell Lung Cancer Metastatic\|Non-small Cell Lung Cancer\|Adenocarcinoma of Lung Metastatic to Brain\|Cerebral Metastases	December 2013	Phase 3
NCT01447225	Merrimack Pharmaceuticals\|Sanofi	Solid Tumors	October 2011	Phase 1
NCT00191503	Eli Lilly and Company	Adenocarcinoma	January 2005	Phase 2
NCT03402048	University of Turin, Italy	Stage IV, NSCLC\|Lung Neoplasms\|Bronchial Neoplasms\|Carcinoma, Bronchogenic\|Lung Diseases\|Neoplasms\|Respiratory Tract Diseases\|Respiratory Tract Neoplasms\|Thoracic Neoplasms	July 2012	Phase 3
NCT00482014	Eli Lilly and Company	Non-Small-Cell Lung Cancer	May 2007	Phase 1\|Phase 2
NCT04194203	Hoffmann-La Roche	Carcinoma, Non-Small-Cell Lung	April 9, 2020	Phase 3
NCT01042288	SCRI Development Innovations, LLC\|Amgen	Non-Small-Cell Lung Cancer	June 2010	Phase 2
NCT04335292	Mark Vincent\|AstraZeneca\|Lawson Health Research Institute	Non-Small Cell Lung Cancer	January 6, 2021	Phase 2
NCT05477615	Jin Hyoung Kang\|Korea University Anam Hospital\|Seoul St. Mary´s Hospital	Non-small Cell Lung Cancer	August 2022	Phase 2
NCT01836341	Memorial Sloan Kettering Cancer Center\|Boehringer Ingelheim\|National Comprehensive Cancer Network	Non-small Cell Lung Cancer	April 2013	Phase 1
NCT01783197	Canadian Cancer Trials Group\|AstraZeneca	Non Small Cell Lung Cancer	January 30, 2013	Phase 1
NCT04455594	The First Affiliated Hospital of Guangzhou Medical University	Non-Small Cell Lung Cancer Stage IIIA	October 2020	Phase 2
NCT01993810	Radiation Therapy Oncology Group\|National Cancer Institute (NCI)\|NRG Oncology	Stage II Non-Small Cell Lung Cancer AJCC v7\|Stage IIA Non-Small Cell Lung Carcinoma AJCC v7\|Stage IIB Non-Small Cell Lung Carcinoma AJCC v7\|Stage III Non-Small Cell Lung Cancer AJCC v7\|Stage IIIA Non-Small Cell Lung Cancer AJCC v7\|Stage IIIB Non-Small Cell Lung Cancer AJCC v7	February 3, 2014	Phase 3
NCT02578680	Merck Sharp & Dohme LLC	Non-Small-Cell Lung Carcinoma	January 15, 2016	Phase 3
NCT00149214	Eli Lilly and Company	Breast Cancer	September 2005	Phase 2
NCT02120807	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Stage IV Lung Adenocarcinoma	April 2014	Phase 1
NCT02980991	Fudan University	Lung Adenocarcinoma	December 2015	Phase 2
NCT00190801	Eli Lilly and Company	Gastrointestinal Neoplasms	September 2003	Phase 2
NCT04611776	Hoffmann-La Roche	Carcinoma, Non-Small Cell Lung	July 1, 2021	Phase 2
NCT00609518	Eli Lilly and Company	Non Small Cell Lung Cancer	February 2008	Phase 2
NCT01784640	Jonsson Comprehensive Cancer Center\|Translational Research in Oncology\|Novartis	Recurrent Non-small Cell Lung Cancer\|Squamous Cell Lung Cancer\|Stage IV Non-small Cell Lung Cancer	January 31, 2014	Phase 1
NCT01209520	University of Miami	Lung Cancer\|Non Small Cell Lung Carcinoma\|Hypermethylation	July 2009	Not Applicable
NCT05527808	Jun Liu\|Guangzhou Institute of Respiratory Disease	Non Small Cell Lung Cancer	August 1, 2022	Not Applicable
NCT02576574	EMD Serono Research & Development Institute, Inc.\|Merck KGaA, Darmstadt, Germany\|EMD Serono	First Line Non-Small Cell Lung Cancer	October 29, 2015	Phase 3
NCT03760575	Abramson Cancer Center of the University of Pennsylvania	Mesotheliomas Pleural	October 28, 2022	Phase 1
NCT03840902	EMD Serono Research & Development Institute, Inc.\|Merck KGaA, Darmstadt, Germany\|EMD Serono	Non-small Cell Lung Cancer	April 16, 2019	Phase 2
NCT02004184	Norwegian University of Science and Technology\|St. Olavs Hospital	Carcinoma, Non-small-cell Lung	December 2013	Phase 3
NCT00006007	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Breast Cancer	December 2000	Phase 2
NCT02407366	People´s Hospital of Guangxi	Non-small Cell Lung Cancer	December 2014	Phase 2
NCT03380468	Fudan University	Lung Neoplasms	January 1, 2018	Phase 2\|Phase 3
NCT02922764	Inspirna, Inc.	Endometrial Cancer\|Endometrial Cancer Recurrent\|Lung Cancer Recurrent\|Lung Cancer\|Non-small Cell Lung Cancer Metastatic\|Non-small Cell Carcinoma	November 2016	Phase 1
NCT02921984	Shanghai Ninth People´s Hospital Affiliated to Shanghai Jiao Tong University	Salivary Gland Tumors\|Head and Neck Cancer	September 2013	Phase 1
NCT00334594	Swiss Group for Clinical Cancer Research	Malignant Mesothelioma	November 14, 2005	Phase 2
NCT01723800	City of Hope Medical Center\|National Cancer Institute (NCI)	Recurrent Non-small Cell Lung Cancer\|Stage IV Non-small Cell Lung Cancer	July 2013	Phase 1
NCT04328844	iOnctura	Solid Tumor, Adult\|Non-Hodgkin Lymphoma, Adult\|NSCLC\|Myelofibrosis\|Uveal Melanoma	February 25, 2020	Phase 1
NCT04379635	BeiGene	Non Small Cell Lung Cancer	May 29, 2020	Phase 3
NCT01567384	Emory University\|OSI Pharmaceuticals	Cancer\|Neoplasms\|Tumors	May 2012	Phase 1
NCT00961415	Hoffmann-La Roche	Non-Squamous Non-Small Cell Lung Cancer	August 2009	Phase 3
NCT02535312	National Cancer Institute (NCI)	Advanced Malignant Solid Neoplasm\|Advanced Peritoneal Malignant Mesothelioma\|Advanced Pleural Malignant Mesothelioma\|Recurrent Peritoneal Malignant Mesothelioma\|Recurrent Pleural Malignant Mesothelioma\|Refractory Malignant Solid Neoplasm\|Unresectable Solid Neoplasm	August 11, 2015	Phase 1\|Phase 2
NCT00268437	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Esophageal Cancer	April 2006	Phase 2
NCT00059865	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Extrahepatic Bile Duct Cancer\|Gallbladder Cancer\|Liver Cancer	January 2004	Phase 1\|Phase 2
NCT03256136	Massachusetts General Hospital\|Bristol-Myers Squibb	Lung Cancer	November 22, 2017	Phase 2
NCT05198830	National Cancer Institute (NCI)	Lung Adenocarcinoma\|Lung Large Cell Carcinoma\|Lung Non-Squamous Non-Small Cell Carcinoma\|Stage III Lung Cancer AJCC v8\|Stage IIIA Lung Cancer AJCC v8\|Stage IIIB Lung Cancer AJCC v8\|Stage IIIC Lung Cancer AJCC v8	May 20, 2022	Phase 2
NCT00297089	AbbVie (prior sponsor, Abbott)\|AbbVie	Lung Cancer\|NSCLC\|Non-Small-Cell Lung Cancer	November 2006	Phase 1\|Phase 2
NCT03737994	National Cancer Institute (NCI)\|NRG Oncology	Lung Non-Squamous Non-Small Cell Carcinoma\|Stage IV Lung Cancer AJCC v8\|Stage IVA Lung Cancer AJCC v8\|Stage IVB Lung Cancer AJCC v8	April 1, 2019	Phase 2
NCT02588781	Samsung Medical Center	Colorectal Cancer	October 2015	Phase 2
NCT03863483	Xin-Hua Xu\|China Three Gorges University, Yichang, China	Nonsquamous Non-Small Cell Lung Cancer	March 26, 2019	Phase 2
NCT00390000	Mayo Clinic\|National Cancer Institute (NCI)	Unspecified Adult Solid Tumor, Protocol Specific	January 25, 2007	Phase 1
NCT01850303	Intergroupe Francophone de Cancerologie Thoracique	Non Small Cell Lung Cancer (Squamous or Non Squamous)	May 16, 2013	Phase 3
NCT00389805	University of California, Davis\|Eli Lilly and Company	Lung Cancer\|Unspecified Adult Solid Tumor, Protocol Specific	March 2005	Phase 1\|Phase 2
NCT01172470	University of Chicago	Head and Neck Cancer	June 2005	Phase 2
NCT01139775	Eli Lilly and Company	Non Small Cell Lung Cancer	February 2011	Phase 1\|Phase 2
NCT00807573	Memorial Sloan Kettering Cancer Center	Lung Cancer	December 2008	Phase 2
NCT00703976	University of Pittsburgh\|Eli Lilly and Company\|Genentech, Inc.	Cancer	October 2008	Phase 2
NCT00550173	Eli Lilly and Company	Non-Small-Cell Lung Cancer	November 2007	Phase 2
NCT00916630	Massachusetts General Hospital\|Beth Israel Deaconess Medical Center\|Eli Lilly and Company\|Dana-Farber Cancer Institute	Central Nervous System Lymphoma	January 2009	Phase 1
NCT01301716	Genentech, Inc.	Solid Cancers	September 2011	Phase 1
NCT02998528	Bristol-Myers Squibb\|Ono Pharmaceutical Co. Ltd	Non Small Cell Lung Cancer	March 4, 2017	Phase 3
NCT03456076	Hoffmann-La Roche	Carcinoma, Non-Small-Cell Lung	August 16, 2018	Phase 3
NCT02542293	AstraZeneca	Non Small Cell Lung Carcinoma NSCLC	November 3, 2015	Phase 3
NCT00864513	Georgetown University\|Eli Lilly and Company	Pancreas Cancer	October 2007	Phase 2
NCT00409006	Eli Lilly and Company	Non-small Cell Lung Cancer	February 2007	Phase 2
NCT01063283	University of Chicago\|Genentech, Inc.	Advanced Non-squamous Non-Small Cell Lung Cancer	March 2010	Not Applicable
NCT00374868	Eli Lilly and Company	Urologic Neoplasms	August 2006	Phase 1\|Phase 2
NCT02864251	Bristol-Myers Squibb\|Ono Pharmaceutical Co. Ltd	Non-Small-Cell Lung Carcinoma	March 17, 2017	Phase 3
NCT01700400	Cancer Research and Biostatistics Clinical Trials Consortium\|University of Arizona\|Providence Cancer Center, Earle A. Chiles Research Institute\|Novartis Pharmaceuticals	Non Small Cell Lung Cancer	September 2012	Phase 1
NCT03671538	Lingyu Luo\|The First Affiliated Hospital of Nanchang University	Non-squamous Non-small Cell Lung Cancer	October 1, 2018	Not Applicable
NCT02087241	AstraZeneca	Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer	March 2014	Phase 2
NCT03086538	Samsung Medical Center	Colo-rectal Cancer	May 30, 2017	Phase 2
NCT01633970	Genentech, Inc.	Cancer	July 11, 2012	Phase 1
NCT02707666	University of Chicago	Pleural Mesothelioma	February 25, 2016	Phase 1
NCT04762459	Cancer Institute and Hospital, Chinese Academy of Medical Sciences\|Jiangsu Hansoh Pharmaceutical Co., Ltd.\|GeneCast Biotechnology Co., Ltd.	Non-small Cell Lung Carcinoma	August 1, 2021	Phase 3
NCT01714037	Debiopharm International SA\|Syneos Health	Non-small Cell Lung Cancer	August 2012	Phase 1
NCT03778138	Henan Provincial People´s Hospital\|Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Non-squamous Cell Non-Small Cell Lung Cancer	January 1, 2019	Phase 2
NCT02930954	Caicun Zhou\|Tongji University	Non-small-cell Lung Cancer	November 2016	Phase 2
NCT00868192	Washington University School of Medicine\|Columbia University	Ovarian Carcinoma\|Primary Peritoneal Carcinoma	May 2008	Phase 2
NCT04768075	Guangdong Association of Clinical Trials	Non-Small-Cell Lung Cancer	March 5, 2021	Phase 3
NCT00824408	Boehringer Ingelheim	Carcinoma, Non-Small-Cell Lung	March 2009	Phase 2
NCT05358548	Rutgers, The State University of New Jersey	Head and Neck Cancer\|Lung Cancer	April 28, 2022	Phase 2
NCT01353482	University College, London\|Merck Sharp & Dohme LLC	Malignant Pleural Mesothelioma		Phase 1\|Phase 2
NCT02624700	Virginia Commonwealth University\|Eli Lilly and Company\|Bayer	Breast Cancer\|Metastatic Breast Cancer\|Recurrent Breast Cancer	January 28, 2016	Phase 2
NCT03562871	IO Biotech\|Merck Sharp & Dohme LLC	NSCLC	August 22, 2018	Phase 1\|Phase 2
NCT00407550	Mayo Clinic\|National Cancer Institute (NCI)	Lung Cancer	November 2006	Phase 2
NCT04339218	Institut Bergonié	Lung Adenocarcinoma\|Cryotherapy Effect	August 28, 2020	Phase 3
NCT01471197	Bristol-Myers Squibb	Lung Cancer - Non Small Cell	July 2012	Phase 2
NCT00892710	SCRI Development Innovations, LLC\|Genentech, Inc.	Non Small Cell Lung Cancer	June 2009	Phase 2
NCT04970043	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Lung Cancer Stage II	July 31, 2021	Not Applicable
NCT02439450	Heat Biologics	Non-small Cell Lung Cancer	April 15, 2015	Phase 1\|Phase 2
NCT01579630	Taipei Veterans General Hospital, Taiwan\|National Taiwan University Hospital\|Taichung Veterans General Hospital\|China Medical University Hospital\|Dalin Tzu Chi General Hospital\|Tri-Service General Hospital	NSCLC	March 2011	Phase 2\|Phase 3
NCT00386815	Eli Lilly and Company	Malignant Pleural Mesothelioma	October 2006	Phase 2
NCT02518802	Tang-Du Hospital	Lung Neoplasms	January 2015	Phase 3
NCT00427466	University Hospital Tuebingen\|Arbeitsgemeinschaft fur Internistische Onkologie\|German Sarcoma Group	Sarcoma	January 2007	Phase 2
NCT02259582	OncoMed Pharmaceuticals, Inc.\|Celgene Corporation\|Mereo BioPharma	Nonsquamous Nonsmall Cell Neoplasm of Lung	February 2015	Phase 2
NCT04166487	Dana-Farber Cancer Institute\|Inivata	NSCLC Stage IV\|Metastatic Non-Small Cell Lung Cancer	January 13, 2020	Phase 2
NCT01774578	NewLink Genetics Corporation\|Lumos Pharma	Non-small Cell Lung Cancer\|Progression of Non-small Cell Lung Cancer\|Non-small Cell Lung Cancer Recurrent	February 2013	Phase 2\|Phase 3
NCT02710396	Naiyer Rizvi\|Merck Sharp & Dohme LLC\|Massachusetts General Hospital\|National Cancer Institute (NCI)\|Columbia University	Carcinoma, Non-Small-Cell Lung	May 31, 2016	Phase 2
NCT05001880	National Cancer Institute (NCI)	Peritoneal Malignant Mesothelioma	October 15, 2021	Phase 2
NCT04136535	Fudan University	NSCLC Stage IV	October 18, 2019	Phase 2
NCT00040625	Eli Lilly and Company	Mesothelioma
NCT02357147	Morphotek	Mesothelioma, Malignant	November 3, 2015	Phase 2
NCT01282151	Chonnam National University Hospital\|Sanofi	Carcinoma, Non Small Cell Lung	July 2011	Phase 3
NCT00698815	National Cancer Institute (NCI)	Recurrent Non-Small Cell Lung Carcinoma\|Stage IIIB Non-Small Cell Lung Cancer AJCC v7\|Stage IV Non-Small Cell Lung Cancer AJCC v7	April 15, 2008	Phase 2
NCT00109096	Eli Lilly and Company	Ovarian Neoplasms\|Primary Peritoneal Cancer	June 2005	Phase 2
NCT03509012	AstraZeneca	Carcinoma, Squamous Cell of Head and Neck\|Carcinoma, Non-Small-Cell Lung\|Small Cell Lung Carcinoma	May 2, 2018	Phase 1
NCT01909830	Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori	Colorectal Cancer Metastatic	July 2012	Phase 2
NCT03850444	Merck Sharp & Dohme LLC	Non-small Cell Lung Cancer	August 1, 2016	Phase 3
NCT04158141	NRG Oncology\|National Cancer Institute (NCI)	Pleural Biphasic Mesothelioma\|Pleural Epithelioid Mesothelioma\|Stage I Pleural Malignant Mesothelioma AJCC v8\|Stage IA Pleural Malignant Mesothelioma AJCC v8\|Stage IB Pleural Malignant Mesothelioma AJCC v8\|Stage II Pleural Malignant Mesothelioma AJCC v8\|Stage IIIA Pleural Malignant Mesothelioma AJCC v8	January 29, 2020	Phase 3
NCT05244837	Hao Long\|Sun Yat-sen University	Tislelizumab\|Safety\|Biomarker\|Chemotherapy	December 22, 2020	Phase 2
NCT04453423	The First Affiliated Hospital with Nanjing Medical University	Non-squamous Non-small-cell Lung Cancer	July 1, 2020	Phase 2
NCT00470405	Vanderbilt-Ingram Cancer Center\|National Cancer Institute (NCI)	Lymphoma\|Solid Tumor	May 2004	Phase 1
NCT00949650	Boehringer Ingelheim	Carcinoma, Non-Small-Cell Lung\|Adenocarcinoma	August 14, 2009	Phase 3
NCT01784549	IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy\|Azienda Sanitaria Locale di Cagliari\|Azienda Ospedaliera San Gerardo di Monza\|Ospedale Santa Croce-Carle Cuneo\|Azienda Ospedaliera S. Maria della Misericordia\|Istituto Tumori Giovanni Paolo II, BARI\|Azienda Ospedaliera dei Colli Monaldi-Cotugno-CTO, Napoli\|Azienda Ospedaliera Santa Maria Degli Angeli\|Azienda Ospedaliera San Camillo Forlanini\|Azienda Ospedaliera San Giovanni Battista\|Azienda Ospedaliera Universitaria Integrata Verona\|Azienda Sanitaria Locale n.2 Savonese\|ASL TO4, Chivasso\|Azienda Provinciale per i Servizi Sanitari, Provincia Autonoma di Trento\|Istituto Clinico Humanitas\|Azienda Ospedaliera Sant´Andrea\|Azienda Ospedaliera, Ospedale Civile di Legnano\|Azienda Ospedaliera Spedali Riuniti di Livorno, Livorno	Non Small Cell Lung Cancer	July 2012	Phase 2
NCT00003711	San Antonio Cancer Institute\|National Cancer Institute (NCI)	Unspecified Adult Solid Tumor, Protocol Specific	September 1997	Phase 1
NCT05132985	Liaoning Tumor Hospital & Institute	NSCLC\|EGF-R Positive Non-Small Cell Lung Cancer	January 1, 2022	Phase 2
NCT04856176	Tufts Medical Center\|Partner Therapeutics, Inc.	Advanced Lung Non-Small Cell Carcinoma\|Non-Small Cell Carcinoma of Lung, TNM Stage 4	January 3, 2022	Phase 2
NCT04832854	Hoffmann-La Roche	Non-Small Cell Lung Cancer (NSCLC)	April 23, 2021	Phase 2
NCT01333696	Fudan University	Squamous Cell Carcinoma of Head and Neck	April 2011	Phase 2
NCT01170871	University of Southern California	Advanced Solid Tumors		Phase 1
NCT04173338	Augusta University	Non Small Cell Lung Cancer\|Non-squamous Non-small-cell Lung Cancer\|Urothelial Carcinoma\|Malignant Mesothelioma	January 23, 2020	Phase 1
NCT00447057	Eli Lilly and Company	Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy.	March 2007	Phase 2
NCT01544179	AstraZeneca	Non-Small Cell Lung Cancer	March 15, 2012	Phase 3
NCT05487391	Qilu Pharmaceutical Co., Ltd.	Carcinoma, Non-Small-Cell Lung	October 1, 2022	Phase 3
NCT01828112	Novartis Pharmaceuticals\|Novartis	Non-Small Cell Lung Cancer	June 28, 2013	Phase 3
NCT00179699	Celgene Corporation\|Prologue Research International\|Celgene	Non-Small Cell Lung Cancer	September 2005	Phase 1
NCT03058094	Hangzhou ACEA Pharmaceutical Research Co., Ltd.\|Cancer Institute and Hospital, Chinese Academy of Medical Sciences	NSCLC	December 2018	Phase 3
NCT04683965	The First Affiliated Hospital with Nanjing Medical University\|Jiangsu Hansoh Pharmaceutical Co., Ltd.	Colorectal Neoplasms	January 1, 2021	Phase 2
NCT03607149	Centre Georges Francois Leclerc	Non-small Cell Lung Cancer	April 6, 2017	Phase 4
NCT03971474	Southwest Oncology Group\|National Cancer Institute (NCI)	Recurrent Lung Non-Small Cell Carcinoma\|Stage IV Lung Cancer AJCC v8\|Stage IVA Lung Cancer AJCC v8\|Stage IVB Lung Cancer AJCC v8	May 28, 2019	Phase 2
NCT04297605	University of Rochester	Non-small Cell Lung Cancer	May 15, 2020	Phase 1
NCT00895648	University Health Network, Toronto\|Eli Lilly and Company	Mesothelioma\|Pleural Mesothelioma	January 2009	Phase 2
NCT01351415	Hoffmann-La Roche	Non-Squamous Non-Small Cell Lung Cancer	June 25, 2011	Phase 3
NCT00859495	Columbia University	Pleural Mesothelioma	February 2008	Phase 2
NCT03137771	NRG Oncology\|National Cancer Institute (NCI)	Recurrent Non-Small Cell Lung Carcinoma\|Stage IV Non-Small Cell Lung Cancer	April 7, 2017	Phase 2
NCT02723578	Yonsei University	Metastatic Colorectal Cancer	December 1, 2015	Phase 2
NCT00065533	Eli Lilly and Company	Breast Cancer	May 2003	Phase 2
NCT00948675	Eli Lilly and Company	Advanced Non-Small Cell Lung Cancer	September 1, 2009	Phase 3
NCT00712062	University of Florida	Primary Central Nervous System Lymphoma	February 2009	Phase 2
NCT00063570	Eli Lilly and Company	Breast Cancer\|Breast Neoplasms	July 2003	Phase 2
NCT02399566	Hunan Province Tumor Hospital	Lung Adenocarcinoma	May 2015	Phase 4
NCT00022646	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Lung Cancer	August 2001	Phase 2
NCT05386888	Genfleet Therapeutics (Shanghai) Inc.	NSCLC, Stage III	September 1, 2022	Phase 2
NCT00071136	Eli Lilly and Company	Lung Neoplasms	December 2003	Phase 1\|Phase 2
NCT03530397	MedImmune LLC	Selected Advanced Solid Tumors	April 24, 2018	Phase 1
NCT00798603	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Lung Cancer	December 2008	Phase 2
NCT02693717	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Metastatic Urothelial Carcinoma	May 9, 2017	Phase 2
NCT00321308	Pfizer	Carcinoma, Non-Small Cell Lung	September 2006	Phase 2
NCT03041181	Nasser Hanna, M.D.\|Hoosier Cancer Research Network\|Bristol-Myers Squibb	Non-Squamous Non-Small Cell Lung Cancer (NSCLC)\|Adenocarcinoma of the Lung\|Lung Cancer\|Squamous Cell Lung Cancer	January 27, 2017	Phase 2
NCT00887549	Eli Lilly and Company	Non-Small Cell Lung Cancer	April 2009	Phase 2
NCT01742767	Universität Duisburg-Essen\|Eli Lilly and Company	NSCLC	November 2012	Phase 2
NCT05048797	AstraZeneca\|Daiichi Sankyo, Inc.	Locally Advanced or Metastatic Non-Small Cell Lung Cancer	October 28, 2021	Phase 3
NCT04971187	M.D. Anderson Cancer Center	Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma\|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma\|Stage III Lung Cancer AJCC v8\|Stage IIIA Lung Cancer AJCC v8\|Stage IIIB Lung Cancer AJCC v8\|Stage IIIC Lung Cancer AJCC v8\|Stage IV Lung Cancer AJCC v8\|Stage IVA Lung Cancer AJCC v8\|Stage IVB Lung Cancer AJCC v8\|Unresectable Lung Non-Squamous Non-Small Cell Carcinoma	June 30, 2021	Phase 2
NCT04351555	AstraZeneca	Non-Small Cell Lung Cancer	December 16, 2020	Phase 3
NCT05273814	Tianjin Medical University Cancer Institute and Hospital	Non-Small Cell Lung Cancer	August 1, 2022	Phase 1
NCT00447421	Eli Lilly and Company	Small Cell Lung Cancer\|Carcinoma, Small Cell\|SCLC	February 2007	Phase 1\|Phase 2
NCT03777124	Jiangsu HengRui Medicine Co., Ltd.\|Shanghai Chest Hospital	NSCLC Stage IV\|KRAS Gene Mutation\|PD-1 Antibody\|Chemotherapy Effect	February 2019	Phase 2
NCT02868892	Western Regional Medical Center	Adenocarcinoma of the Cervix\|Adenosquamous Cell Carcinoma of the Cervix	July 2015	Phase 2
NCT00325234	Eli Lilly and Company	Breast Cancer	June 2006	Phase 2
NCT02804646	Anhui Provincial Hospital	Adenocarcinoma of Lung	June 2016	Phase 4
NCT03762018	ETOP IBCSG Partners Foundation\|Hoffmann-La Roche	Pleural Mesothelioma Malignant Advanced	April 30, 2019	Phase 3
NCT00806819	Boehringer Ingelheim	Carcinoma, Non-Small-Cell Lung	December 2008	Phase 3
NCT00523419	Eli Lilly and Company	Osteosarcoma	September 2007	Phase 2
NCT04956692	Merck Sharp & Dohme LLC	Non-Small Cell Lung Cancer	August 5, 2021	Phase 3
NCT00738881	National Cancer Institute (NCI)\|Cancer and Leukemia Group B\|Eastern Cooperative Oncology Group\|NCIC Clinical Trials Group\|Southwest Oncology Group	Recurrent Non-Small Cell Lung Carcinoma\|Stage IIIA Non-Small Cell Lung Cancer\|Stage IIIB Non-Small Cell Lung Cancer\|Stage IV Non-Small Cell Lung Cancer	October 2008	Phase 3
NCT00227630	European Organisation for Research and Treatment of Cancer - EORTC	Malignant Mesothelioma	July 2005	Phase 2
NCT01109615	Vejle Hospital	Metastatic Colorectal Cancer	April 2010	Phase 2
NCT04470674	Shirish M Gadgeel\|AstraZeneca\|Henry Ford Health System\|Hoosier Cancer Research Network	Lung Cancer\|Non-small Cell Lung Cancer\|PD-L1 Gene Mutation\|KRAS Activating Mutation	April 6, 2021	Phase 2
NCT04203485	Jiangsu HengRui Medicine Co., Ltd.	PD-L1 Positive Non-small Cell Lung Cancer	June 15, 2020	Phase 3
NCT01218516	Morphotek	Adenocarcinoma of the Lung	June 27, 2011	Phase 2
NCT05394233	Sichuan Cancer Hospital and Research Institute	Non-squamous Non-small Cell Lung Cancer\|EGFR Gene Mutation	June 1, 2022	Phase 2
NCT01017874	Eli Lilly and Company	Non Small Cell Lung Cancer	November 2009	Phase 3
NCT00745875	AstraZeneca	Non Small Cell Lung Cancer\|Lung Cancer	August 2008	Phase 2
NCT01935947	National Cancer Institute (NCI)	Recurrent Non-Small Cell Lung Carcinoma\|Stage IIIA Non-Small Cell Lung Cancer\|Stage IIIB Non-Small Cell Lung Cancer\|Stage IV Non-Small Cell Lung Cancer	May 2013	Phase 2
NCT00072865	Eli Lilly and Company	Breast Cancer\|Neoplasm Metastasis	June 2003	Phase 2
NCT02182102	Boehringer Ingelheim	Carcinoma, Non-Small-Cell Lung	September 2005	Phase 1
NCT02041533	Bristol-Myers Squibb\|Ono Pharmaceutical Co. Ltd	Stage IV or Recurrent Non-Small Cell Lung Cancer	March 27, 2014	Phase 3
NCT01674738	Aktion Bronchialkarzinom e.V.\|Roche Pharma AG\|Eli Lilly and Company	Carcinoma, Non-Small-Cell Lung		Phase 2
NCT04042558	Centre Francois Baclesse\|GFPC	NSCLC Stage IIIB\|NSCLC Stage IV\|EGFR Gene Mutation\|ALK Gene Rearrangement Positive\|ROS1 Gene Mutation	September 26, 2019	Phase 2
NCT05116462	Innovent Biologics (Suzhou) Co. Ltd.	Non-small Cell Lung Cancer (NSCLC)	November 11, 2021	Phase 3
NCT04287894	The Netherlands Cancer Institute\|AstraZeneca	Stage III NSCLC	December 28, 2018	Phase 1
NCT03456063	Hoffmann-La Roche	Non-Small-Cell Lung	April 24, 2018	Phase 3
NCT00191191	Eli Lilly and Company	Non-small Cell Lung Cancer	October 2004	Phase 2
NCT04439890	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Advanced Non-squamous Cell Non-small Cell Lung Cancer	August 8, 2019	Phase 3
NCT00295503	University of Texas Southwestern Medical Center\|University of Chicago\|Columbia University\|Duke University	Mesothelioma	February 2006	Phase 2
NCT02079636	Eli Lilly and Company\|Merck Sharp & Dohme LLC	Carcinoma, Non-small Cell Lung	March 28, 2014	Phase 1
NCT04163432	University of Utah\|AstraZeneca	Non-Small Cell Lung Cancer Metastatic	June 16, 2020	Phase 2
NCT01232452	Eli Lilly and Company	Non-Small-Cell Lung Carcinoma	April 2011	Phase 2
NCT03193788	Asan Medical Center\|Korean Cancer Study Group	Bladder Cancer\|Ureter Cancer\|Transitional Cell Carcinoma	January 2017	Phase 3
NCT05253118	Seoul National University Hospital\|Seoul National University Bundang Hospital	DLBCL	August 18, 2022	Phase 2
NCT05185544	Shanghai Zhongshan Hospital	Sensitivity	January 1, 2022
NCT04177953	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest\|Bristol-Myers Squibb	Pleural Mesothelioma Malignant	February 4, 2019	Phase 2
NCT00356525	Eli Lilly and Company	Lung Neoplasms	September 2006	Phase 2
NCT00259285	Eli Lilly and Company	Non-Small-Cell Lung Cancer	November 2005	Phase 2
NCT00230542	Dana-Farber Cancer Institute\|Massachusetts General Hospital\|Brigham and Women´s Hospital	Ovarian Cancer\|Peritoneal Cancer\|Fallopian Tube Cancer	September 2005	Phase 2
NCT04892953	M.D. Anderson Cancer Center	Stage III Lung Cancer AJCC v8\|Stage III Lung Non-Small Cell Cancer AJCC v7\|Stage IIIA Lung Cancer AJCC v8\|Stage IIIA Lung Non-Small Cell Cancer AJCC v7\|Stage IIIB Lung Cancer AJCC v8\|Stage IIIB Lung Non-Small Cell Cancer AJCC v7\|Stage IIIC Lung Cancer AJCC v8	July 31, 2021	Phase 2
NCT00942825	CanBas Co. Ltd.	Metastatic Non-squamous Non Small Cell Lung Cancer	April 2009	Phase 2
NCT05507606	Tianjin Medical University Cancer Institute and Hospital	Non Small Cell Lung Cancer	August 1, 2021	Phase 2
NCT01469000	Eli Lilly and Company	Carcinoma, Non Small Cell Lung	February 2012	Phase 2
NCT02453282	AstraZeneca	Non-Small-Cell Lung Carcinoma NSCLC	July 21, 2015	Phase 3
NCT00415168	Eli Lilly and Company	Gastric Cancer	December 2006	Phase 2
NCT01443078	Memorial Sloan Kettering Cancer Center\|Eli Lilly and Company\|United States Department of Defense	Lung Cancer	October 2011	Phase 2
NCT00974584	Genentech, Inc.	Non-Squamous Non-Small Cell Lung Cancer	October 2009	Phase 1
NCT01565538	Si-Yu Wang\|Sun Yat-sen University	Lung Cancer	December 2008	Phase 2
NCT04754815	Shirish Gadgeel\|Merck Sharp & Dohme LLC\|Henry Ford Health System	Non Small Cell Lung Cancer\|Advanced Lung Non-Small Cell Carcinoma\|PD-L1 Gene Mutation	April 1, 2021	Phase 2
NCT02367781	Hoffmann-La Roche	Carcinoma, Non-Squamous Non-Small Cell Lung	April 16, 2015	Phase 3
NCT00732303	Hoosier Cancer Research Network\|Eli Lilly and Company	Non-Small Cell Lung Cancer	January 2009	Phase 2
NCT03138889	Nektar Therapeutics	Non-Small Cell Lung Cancer	June 9, 2017	Phase 1\|Phase 2
NCT00191347	Eli Lilly and Company	Breast Cancer	October 2004	Phase 2
NCT00769600	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Recurrent Non Small Cell Lung Cancer	November 2008	Phase 2
NCT03655834	Radboud University Medical Center\|ZonMw: The Netherlands Organisation for Health Research and Development	Non Small Cell Lung Cancer\|Mesothelioma	February 1, 2019	Phase 4
NCT01918761	Central European Cooperative Oncology Group	Non Small Cell Lung Cancer	July 30, 2013	Phase 1
NCT00003706	The University of Texas Health Science Center at San Antonio\|Lily Research Laboratories\|National Cancer Institute (NCI)	Unspecified Adult Solid Tumor, Protocol Specific	April 1998	Phase 1
NCT03425643	Merck Sharp & Dohme LLC	Non-small Cell Lung Cancer	April 24, 2018	Phase 3
NCT00932893	Pfizer	Carcinoma, Non-Small-Cell Lung	September 2009	Phase 3
NCT00372788	AstraZeneca	Non-small Cell Lung Cancer	August 2006	Phase 2
NCT00589667	Memorial Sloan Kettering Cancer Center	Head and Neck Cancer	September 2006	Phase 2
NCT00456261	SCRI Development Innovations, LLC\|Genentech, Inc.\|Eli Lilly and Company	Lung Cancer	March 2007	Phase 2
NCT01192165	GlaxoSmithKline	Cancer	September 14, 2010	Phase 1
NCT03574402	Guangdong Association of Clinical Trials\|Chinese Thoracic Oncology Group	Carcinoma, Non-Small-Cell Lung	July 9, 2018	Phase 2
NCT00276783	Northwestern University\|National Cancer Institute (NCI)	Brain and Central Nervous System Tumors\|Lymphoma\|Metastatic Cancer	November 2005	Phase 2
NCT02117167	UNICANCER\|Intergroupe Francophone de Cancerologie Thoracique\|Fondation ARC\|AstraZeneca	Non-small Cell Lung Cancer Metastatic	April 23, 2014	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H ₂ O : 100 mg/mL ( 193.64 mM ; Need ultrasonic)

DMSO : 2 mg/mL ( 3.87 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9364 mL	9.6822 mL	19.3645 mL
5 mM	0.3873 mL	1.9364 mL	3.8729 mL
10 mM	0.1936 mL	0.9682 mL	1.9364 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 33.33 mg/mL (64.54 mM); Clear solution; Need ultrasonic

* All of the co-solvents are available by MCE.